Table Of Content

Author Index, Volume 35 (1995) Abdelwahab W, 747 Brecher MB, 713 Davis S, 295 Ford NF, 145, 785 Abernathy T, 588 Brion JD, 298 De Castro S, 627 Forrest A, 807 Abernethy DR, 794 Bruera E, 666 de Vries A, 357 Foster RT, 1076 Affrime M, 856 Bryzinski BS, 182 Dean R, 688 Fowles RE, 673 Affrime MB, 151 Buckley SJ, 1144 Dee CM, 721 Fox AAL, 233, 794 Albrink MH, 1046 Bugge C, 606 Del Rosso A, 176 Fozailoff A, 943 Alemayehu D, 182 Bulle T, 673 Derendorf H, 302, 885, 1187 Franco J, 856 Alexander S, 673 Burris JF, 182, 337 Desiraju RK, 379 Freeman R, 314 Alfurayh O, 1003 Bury M, 821 Dett C, 856 Freundlich NL, 521, 840 Ali H, 615 Deutsch PJ, 1008 Frishman W, 314, 747 Almar MM, 895 Caille P, 633 DeVane CL, 876 Frishman WH, 182, 541, Alpert BS, 268 Calvo B, 426 Dhaliwal HS, 37 943, 1060 Altieri LP, 876 Campbell NRC, 275 D’Hautefeuille B, 471 Fromell G, 189 Al-Uzri A, 856 Capra NL, 1200 Di ZS, 510 Fruncillo R, 1194 Amer M, 1003 Carter BL, 81 Dies F, 800 Fruncillo RJ, 404 Amidon GL, 374 Cartoni D, 627 DiLea C, 957 Fujii I, 995 Archer S, 189 Causey D, 985 Dileo EM, 688 Fujimura A, 776, 1067 Armand P, 633 Cavanaugh JM, 815 Dillon KR, 1046 Fulmor IE, 730, 785, 1109 Arns W, 1136 Cediel M, 885 Dingemanse J, 821 Funaro S, 627 Arora S, 840 Cerimele BJ, 170 Dockens RC, 730 Atkinson L, 1083 Chaikin PC, 730 Dominguez-Gil A, 426 Gad A, 17 Aweeka FT, 856, 967 Chaleby K, 17 Donsky J, 295 Gaillard AWK, 821 Awni WM, 379 Chan K, 390 Dossing M, 615 Galia EF, 1187 Chang C-L, 250 Driver MR, 505 Gambertoglio JG, 856, 967 Babul N, 37, 666 Chang C-T, 865 Du Plooy WJ, 244 Gammans RR, 974 Babuty D, 471 Chang W-H, 128 Duerr H, 721 Garcia-Ortega E, 426 Bachmann K, 529 Charles B, 31 Durrieu G, 633 Garland WT, 780 Bakris GL, 72, 073 Charnick S, 865 d’Uscio CH, 967 Garner DM, 22 Barbhaiya RH, 432, 830, Chautsane Z, 1052 Duursema L, 306 Garnett WR, 526 974 Chen H, 128 Dye D, 259 Garovoy MR, 967 Barclay KD, 1144 Chen S-Y, 182 Garzarella L, 885 Barr WH, 721 Chi E, 713 Ebel DL, 362 Gascon AR, 426 Barth J, 302, 1187 Chiang J, 1094 Ebihara A, 776 Gasperini C, 627 Bastian HL, 606 Chiang S, 1194 Eff J, 189 Gath J, 31 Batlle D, 87 Chiang ST, 404, 410 Eggers H, 1103 Gavish D, 599 Battle M, 763 Chopamba A, 1052 Eisner GM, 484 Gibaldi M, 647, 1031 Beigel Y, 599 Chow MSS, 11S, 1S Elder CA, 865 Gieschke R, 821 Beller B, 673 Christ DD, 515 Eldon MA, 622 Gil A, 420 Benedek IH, 1181 Christopher D, 151 Eller M, 493 Giles TD, 673 Benedict CR, 705 Chrysant SG, 189, 239, 1060 Elliott WJ, 98 Giustina A, 285 Benet LZ, 967, 1094 Cilla DD, 990 El-Yazigi A, 17, 615, 1003 Glasser SP, 780 Beni S, 627 Cipriano A, 390 Erdmann M, 302, 1187 Goerdt C, 767 Benslimane AF, 298 Cleophas TJM, 594 Ernst P, 615 Goldberg MJ, 170 Berger ML, 362 Codispoti J, 45 Ersboll BK, 606 Goldberg MR, 1008, 1200 Berkovitch M, 295 Cogan MG, 1094 Ezzat S, 59 Golden JA, 1166 Berlin I, 633 Cohen A, 865 Goldenheim PD, 499 Betrabet SS, 1025 Cohen M, 239 Fagan TC, 52 Goldfarb AL, 196 Bhatti MM, 1076 Cohen RI, 398 Fainaru M, 599 Gonzalez A, 420 Bisi G, 176 Colburn WA, 441, 464, 655 Fainsinger R, 666 Gonzalez-Gallego J, 895 Bittar N, 780 Colfer H, 673 Ferdinand K, 45 Gonzalez-Sastre M, 895 Bjornsson TD, 362, 1008 Collins JF, 170 Ferdinand KC, 52 Goodman AM, 1094 Bleske BE, 374 Conte JE, 1166 Fiddes R, 189 Gorsline J, 259, 493, 985 Blumer JL, 658 Cornac A, 697 Figg WD, 368 Graff A, 1060 Bockbrader HN, 622 Cramer M, 705 Fillit H, 25S Grandy RP, 499 Bootsma G, 357 Curry C, 45 Fisher MB, 673 Grasing K, 713 Borin MT, 505 Cutler DL, 856 Fiske WD, 22 Graves JE, 885 Borzak S, 902 Cutler NR, 189, 800 Fitoussi S, 633 Gray AL, 1020 Botha JH, 1020 Flannery BE, 151 Greene DS, 974 Bourge RC, 673 Dal-Ré R, 420 Fliickiger SS, 681 Griffiths L, 688 Boxenbaum H, 763, 957 Darke AC, 37, 666 Follin SL, 351 Groenewoud G, 306 Branebjerg PE, 606 Davis CM, 128 Foote EF, 384 Grover J, 673 Brass EP, 189 Davis PJ, 52 Forbes KK, 505 Guerciolini R, 521, 856 Guillen GJ, 885 Kahn J, 856 Lin ET, 1094 Natarajan C, 688, 785 Guinta D, 259 Kaihlanen PM, 233 Lin S-K, 128 Nayak RK, 137, 379 Gupta SK, 159, 202, 493, Kaiko RF, 499 Links TP, 291 Nedelman J, 865 967, 985, 1083 Kakinoki S, 510 Lison AE, 1136 Nelluri SN, 588 Guzzo C, 865 Kallay Z, 681, 1136 Liu CY, 1094 Neuman Y, 599 Giiell A, 697 Karara AH, 865 Ljutic D, 1150 Nix DE, 196 Gyermek L, 845 Karim A, 384 Lloyd T, 202 Nomura A, 510 Karol MD, 815 Lo M-W, 1200 Norholt SE, 606 Hagen N, 37 Kaul S, 830 Longstreth J, 1083 Nozaki S, 478 Hahne WF, 705 Kazierad DJ, 151, 196, 807 Louie J, 259 Haidar S, 1174 Keane WF, 384, 622 Lowe N, 865 O’Connell MB, 18S Halabi A, 107 Kearns GL, 343, 739 Lowenthal DT, 885 Odink J, 821 Hall ST, 1174 Keefe DL, 1119 Lucki I, 410 O’Donnell D, 142 Halstenson CE, 137, 379, Keilani T, 87 Luke DR, 281 Ohashi K, 1067 384, 622 Keith M, 767 Ohmori K, 478 Hamel L, 259 Kemp SF, 739 Machinist JM, 815 Okerholm RA, 493 Hammett JL, 145 Kezer EA, 398 Mahachai V, 1071 Okin S, 541 Han R, 362 Kim YS, 22 Mak M, 856 Olivieri NF, 295 Harada K, 776, 1067 King JD, 529 Mammen E, 1194 Olsen KM, 739 Harris AG, 59 King S-YP, 1181 Mandal AK, 588 Onelli E, 285 Harsanyi Z, 37, 666 Kirch W, 107 Manning J, 145 Opsahl JA, 137, 379 Headlee D, 368 Kirdeikis P, 1071 Marathe PH, 974, 1109 Ordelova A, 351 Heimark L, 151 Kirshner M, 876 Marriage B, 1071 Osborne B, 1008 Hernandez RM, 426 Kishino S, 510 Martz R, 22 Ozawa T, 1194 Hinderling PH, 721 Kitabatake A, 510 Masotti G, 176 Hinrichsen H, 107 Klassen GA, 1144 Matsui D, 295 Padhi ID, 902 Hintze TH, 688 Klockowski PM, 410 Matsuo H, 478 Pan HY, 142 Hirabayashi K, 478 Kodama H, 995 Matzke GR, 137, 379 Panton LB, 885 Hochhaus G, 302, 1187 Kodama Y, 995 Mayol RF, 974 Parker BM, 673 Hoelscher DD, 73 Kokoris SP, 59 McCrea JB, 1200 Parker VD, 404, 410 Holloway S, 1194 Kombo I, 1025 McMahon FG, 484, 1060 Passe SM, 840 Hoover ME, 362 Kong A-NT, 1008 McNally C, 45 Pasutto FM, 1076 Houin G, 697 Koren G, 295 Mediratta S, 943 Patat A, 633 Hourani J, 800 Kornhauser DM, 1181 Mehta AV, 1016 Patel IH, 521, 1103 Hsieh JY-K, 1200 Kosoglou T, 151 Melia AT, 521, 840, 1103 Patel SB, 1025 Hsu H, 1060 Koss-Twardy SG, 281, 521, Meligeni J, 865 Patrick JE, 151 Hsu RS, 688 840 Metz A, 202 Pavy-Le Traon A, 697 Hu OY-P, 250 Kovarik JM, 1136 Meyer A, 681 Pedraz JL, 426 Hubbard JW, 688, 713 Krepostman A, 902 Middle MV, 306 Peirgies AA, 410 Huberfeld S, 541 Krumerman J, 885 Milbrath RL, 730 Peraudeau P, 471 Hui KK, 785 Kulkarni RD, 1025 Milla G, 521 Perel JM, 202 Hulse JD, 464 Kumagai Y, 1067 Millefiorini E, 627 Peter K, 856 Hundt HKL, 306 Kumar A, 541 Miller K, 529 Petit J-Y, 298 Hung OR, 1144 Kunka RL, 202 Miller R, 1020 Phelps SJ, 268 Hunt TL, 705 Kupiec JW, 1060 Min B, 521 Pieniaszek HJ, 1181 Hurley Dj, 800 Kuranari M, 995 Min BH, 840 Pieniaszek HJ Jr, 22 Hussey EK, 1174 Kurto HA, 1046 Minn FL, 379 Pieper JA, 268 Hwang SS, 159, 259, 985 Kutz K, 681 Miyazaki K, 510 Piepho RW, 443 Molinier P, 633 Piraino AJ, 390 Imbimbo BP, 285 La Cava G, 176 Moore M, 865 Piscitelli SC, 368 Ingenito AJ, 117 Lam YWF, 128 Morgan JM, 390 Pittman KA, 974 Iseki K, 510 Landau A, 747 Morganroth J, 163 Poggesi L, 176 Lantz MV, 967 Morino S, 627 Pollak PT, 1144 Jain AK, 45, 484 Lasheras L, 420 Morita H, 478 Pollock BG, 876 Jallad NS, 45 Lasseter KC, 145 Morris DM, 1174 Pollock ML, 885 Jamali F, 1071 Lathers CM, 333, 573, 1120 Mosca A, 285 Posvar EL, 990 James LP, 343 LeClair IO, 1016 Mollmann H, 302, 1187 Pouchus YF, 298 Jann MW, 128 Lee A, 1052 Mroczek WJ, 182 Pozuelo M, 895 Jauregui L, 529 Lee DR, 384 Mueller EA, 1136 Pritchard JF, 137 Jessup M, 673 Lee JS, 432, 1109 Muriel C, 426 Prueksaritanont T, 967 Jin J, 865 Lee JW, 464 Miller OF, 306 Pruvost P, 471 Johnson BF, 484 Levine JH, 52 Mycinsky C, 471 Johnston A, 681 Lewanczuk RZ, 1076 Mydlow PK, 1174 Radulovic LL, 990 Joly R, 1103 Licini M, 285 Myers CE, 368 Radwanski E, 151 Jorquera F, 895 Lieberman R, 368 Raines DA, 17, 615 Joshi AS, 1181 Lima JJ, 268 Nademanee K, 780 Rajagopalan R, 526 Joshi JC, 390 Lin CC, 1200 Naggar C, 673 Ram CVS, 1060 1210 Raymond R, 145 Schentag JJ, 151, 196 Sullivan TJ, 529 Wahab FA, 615 Raymond RH, 730, 1109 Schettino M, 285 Sun JX, 390 Waldman SA, 163, 1008 Redalieu E, 390 Schlueter W, 87 Sunaga K-I, 776 Wang Y-H, 541 Reddy K, 1052 Schmidt C, 681 Svensson CK, 902 Ward JL, 268 Reder RF, 499 Schnaper HW, 45 Sweet RA, 876 Wardle TS, 800 Reece PA, 526 Schraeder PL, 573, 1120 Simunic M, 1150 Ware JA, 902 Reed MD, 658 Schwartz J, 314, 529 Webb CR, 351, 902 Reese JH, 529 Schwartz JI, 362 Wei G, 493 Reitsma WD, 291 Sciagra R, 176 Takeyama M, 995 Weidler D, 45 Renner E, 1136 Scott M, 529 Tallarico D, 627 Weidler DJ, 673 Rice PJ, 1016 Sedman AJ, 526, 622, 990 Tam YK, 275 Weinberg J, 1052 Ripa S, 780 Seiberling M, 721 Tang H-S, 250 Weir MR, 73, 182, 220 Ritter W, 306 Shah A, 705 Tavenier P, 594 Weiss R, 780 Robertson S, 275 Shareef B, 541 Tavernini M, 1071 Welage LS, 374 Robinson D, 974 Shea MJ, 374 Taylor AM II, 807 Welin L, 298 Rock WL Jr, 526 Shukla UA, 830, 974 Taylor JR, 526 Wertheimer J, 673 Rohatagi S, 302, 1187 Shyu WC, 432 Teller SB, 281 Whelton A, 233, 454 Rolf CN, 493, 985 Sieck JO, 615 Tendolkar A, 721 Whipple JP, 673 Roncari G, 821 Simon JS, 182 Teplitzky Y, 599 White RM, 1156 Rongen GA, 357 Simpson I, 1071 Thibault A, 368 White WB, 233 Rose S, 374 Simpson K, 865 Thien T, 357 Whitfield LR, 990 Rosemurgy AS II, 1046 Sindet-Pedersen S, 606 Thirlwell MP, 37 Williams L, 885 Rowe HM, 170 Singh S, 780 Thomson ABR, 1071 Wilson JM, 398 Rubins HB, 767 Skerjanec A, 275 Tisdale JE, 351, 902 Wilson MF, 807 Rudd P, 484 Skoularigis J, 1052 Toddywalla VS, 1025 Wilton JH, 807 Rudis MI, 902 Smit AJ, 291 Tomasko L, 362, 1008, 1200 Wittkowsky AK, 1031 Rudolph G, 202 Smith BL, 840 Tomlanovich SJ, 967 Wojcik GJ, 196 Rumboldt Z, 1150 Smith E, 673 Tompkins A, 368 Wong MO, 622 Smith ER, 398 Topmiller MJ, 52 Wooles WR, 117 Sackler RS, 499 Smith HT, 1136 Toth PD, 45 Wright B, 876 Sagraves R, 2S Smith RA, 785 Triscari J, 142 Wurzel M, 599 Sainati SM, 713 Smithurst B, 31 Troy S, 1194 Saivin S, 697 Smits P, 357 Troy SM, 404, 410 Xilinas M, 22 Salazar DE, 730, 1109 Sourgens H, 302, 1187 Tsutsumi K, 995 Sambol NC, 1094 Southam MA, 159 Tiirck D, 622 Yamashita TS, 658 Samid D, 368 Sowers JR, 484 Yeh KC, 362, 529 Sampson J, 31 Sowinski KM, 807 Uderman HD, 730, 1109 Yeung PFK, 1144 Sansegundo D, 895 Spachynski K, 666 Underwood B, 526 Yih BM, 1083 Sardelic S, 1150 Sramek JJ, 800 Underwood BA, 622 Yoshikawa K, 478 Sareli P, 1052 Srinivas NR, 432 Upmalis D, 432 Yu H-S, 128 Sasaki M, 776 Stauffer LA, 362 Yuen GJ, 1174 Satoh H, 281 Stepanavage M, 529 Satterwhite JH, 800 Stewart W, 705 van Brummelen P, 821 Zafrir N, 599 Saxena BN, 1025 Stimpel M, 233, 794 Van Harken DR, 145 Zarowitz BJ, 902 Saxton TD, 22 Stitzel V, 588 Vara F, 426 Zecca L, 285 Schafer AI, 209 Stokes A, 45 Venter CP, 244 Zell M, 821 Schall! R, 306 Stone WL, 1016 Ver Donck K, 357 Zhi J, 281, 521, 840, 1103 Schange SJ, 398 Strugo V, 1052 Verbist J-F, 298 Zinny M, 142 Scheck F, 471 Sugawara M, 510 Vivas C, 885 Zuk L, 1071 Subject Index, Volume 35 (1995) Acetaminophen Adverse Effects BRL 49653C pharmacokinetics and, A926 for muscle-contraction headache, A929 amiodarone noncardiovascular adverse effects, CGP 36742 pharmacokinetics and, A922 for orthodontic pain in children, A929 351 linopirdine in healthy young adults and elderly Acromegaly enalapril, 484 volunteers, 22 subcutaneous octreotide infusion for, 59 isradipine, 484 metformin pharmacokinetics and, 1094 Adolescents. See Pediatrics mitoxantrone, 627 sibutramine pharmacokinetics and, A928 Adrenaline tyramine during benfloxatone treatment, 633 Albumin interaction with lidocaine, 426 Age. See also Geriatrics; Pediatrics interferon alfa-2a bioequivalency, 281 Adrenocorticotropic Hormone aging effects on antipyrine clearance, 895 Aldosterone losartan effects on response of cortisol and aldo- atenolol pharmacokinetics and pharmacody- losartan effects on response to adrenocortico- sterone to, 776 namics and, 807 tropic hormone, 776 Alosetron Antithrombotic Therapy Butorphanol Tartrate Nasal Spray interaction with haloperidol, 202 heparin in, 1031 interaction with sumatriptan succinate, 432 Alpha-1-Acid Glycoprotein Anuria disopyramide protein binding and, 510 gabapentin disposition subjects on hemodialysis, Calcium Antagonists. See also specific agents Alprostadil 622 for congestive heart failure, 443 efficacy and safety in erectile dysfunction, A937 Ardeparin Cancer. See Oncology Altitude. See High Altitude pharmacokinetics, 1194 Carbamazepine Alzheimer’s Disease Area Under the Inhibitory Curve pharmacokinetics, 995 xanomeline tartrate safety and efficacy in, 800 as target for optimization of dosing regimens of Carbamazepine-10 American College of Clinical Pharmacology antibiotics, A926 pharmacokinetics, 995 symposium from 1993 annual meeting, 72 Arrhythmias Carbimazole Amiodarone atropine effects on parasympathetic control of re- interaction with digoxin, A922 noncardiovascular adverse effects, 351 spiratory sinus arrhythmia, 244 Carboplatin Amitriptyline cibenzoline versus flecainide in prevention of pharmacokinetics, 1003 enzyme kinetic modeling as tool in identifying paroxysmal atrial arrhythmias, 471 Cardiopulmonary Resuscitation metabolic pathways, A926 inability to tolerate long term drug therapy as in- regional blood flow measurement during, A935 pharmacokinetics, 17 dication for radiofrequency catheter ablation Cardiovascular System. See also Antihyperten- Amlodipine of supraventricular arrhythmias, A927 sive Agents; Arrhythmias; Hypertension amlodipine and benazepril monotherapy com- Aspirin amiodarone noncardiovascular adverse effects, pared with amlodipine plus benazepril in sys- pharmacodynamics, 1181 351 temic hypertension, 1060 pharmacokinetics, 1181 amlodipine and benazepril monotherapy com- Amrinone Asthma pared with amlodipine plus benazepril in sys- venodilatory effect compared with theophylline, computer-based system of instruction on new temic hypertension, 1060 1067 perspectives in prevention and treatment of, amlodipine effects in black patients with very se- Analgesics. See also Nonsteroidal anti-inflam- vere hypertension, 1052 matory drugs; specific analgesics Atenolol amrinone and theophylline venodilatory effects lornoxicam, 606 pharmacodynamics, 807 compared, 1067 morphine, 666 pharmacokinetics, 268, 807 anthracycline cardiotoxicity, A935 over-the-counter, renal effects of, 454 Atorvastatin antianginal and antiischemic efficacy of nisoldip- Anesthetics pharmacokinetics, 990 ine in chronic stable angina, 780 eutectic mixture of local anesthetics for pro- Atropine atropine effects on parasympathetic control of re- longed subcutaneous drug administration, 295 parasympathetic control of respiratory sinus ar- spiratory sinus arrhythmia, 244 Angina rhythmia and, 244 calcium antagonist therapy for congestive heart antianginal and antiischemic efficacy of nisoldip- failure, 443 ine in chronic stable angina, 780 cardiovascular actions and cardioprotective ben- dose-ranging study ofd iltiazem for stable angina, Benazepril efits of estrogen replacement therapy in post- 189 amlodipine and benazepril monotherapy com- menopausal women, 306 Angiotensin-Converting Enzyme Inhibitors. See pared with amlodipine plus benazepril in sys- cardiovascular pharmacokinetics of bespiridine also specific agents temic hypertension, 1060 hydrochloride, 688 for hypertension, 337 Benfloxatone cibenzoline versus flecainide in prevention of in renal disease, 87 adverse effects, 633 paroxysmal atrial arrhythmias, 471 Angiotensin-II Bepridil diltiazem dose-ranging study for stable angina, valsartan pressor response to, A930 pharmacokinetics, 137, 379 189 Anthracycline Bespiridine Hydrochloride diltiazem for hypertension, 220 cardiotoxicity of, A935 pharmacokinetics, 688 dolasetron dose-ranging safety evaluation, 713 Antibiotics. See also specific agents Bidisomide fosinopril pharmacodynamics in congestive area under the inhibitory curve as target for opti- food and absorption and disposition profiles of, heart failure, 785 mization of dosing regimens of, A926 A921 head-down tilt effects on lidocaine pharmacoki- Antidepressant Agents. See also specific agents food and plasma levels of, A921 netics as probe to evaluate hepatic blood flow, cyclic antidepressant toxicity in children and ad- Bioavailability. See Pharmacokinetics 697 olescents, 343 Bioequivalence H,-receptor antagonist effects, 107 Antiepileptic Agents. See also specific agents interferon alfa-2a and human serum albumin iloperidone pharmacokinetics, 713 clinical pharmacology of, 1120 content, 281 isradipine-CR for sustained blood pressure con- experience-based teaching of therapeutics and morphine using naltrexone blockade, 499 trol, 239 clinical pharmacology of, 573, A940 statistical difference in analysis of variance and, lisinopril for heart failure, 673 Antihypertensive Agents. See also Renal Func- A931 losartan effects on response of cortisol and aldo- tion; specific agents verapamil sustained-release formulations, 163 sterone to adrenocorticotropic hormone, 776 indapamide, 45 Bisoprolol lovastatin effects on early restenosis, 599 verapamil, 52 low-dose, with low-dose hydrochlorothiazide for low-dose bisoprolol and low-dose hydrochloro- Antiinflammatory Agents. See also specific hypertension, 182 thiazide therapy, 182 agents Blood Flow mexiletine effects on left ventricular contractil- cordiachromene A, 298 regional blood flow measurement during cardio- ity in congestive heart failure, 478 platelet function and systemic hemostasis and, pulmonary resuscitation, A935 mitoxantrone cardiotoxicity in relapsing remit- 209 Blood Pressure. See also Antihypertensive ting multiple sclerosis, 627 triamcinolone acetonide pharmacokinetics, 302, Agents; Hypertension moexipril efficacy assessment, 233 1187 gender differences in exercise and recovery moexipril versus verapamil for mild to moderate triamcinolone acetonide pharmacodynamics, blood pressures in normal volunteers given dil- hypertension, 794 1187 tiazem, 1144 phentolamine antagonism of norepinephrine-in- Antimicrobial Agents. See also Antibiotics; spe- Body Position duced hand vein constriction, 170 cific agents norverapamil pharmacokinetics and pharmaco- phenytoin effects on plasma high-density lipo- quantitative evaluation of activity on the hand dynamics, 1083 protein cholesterol levels in men with low lev- using intrapersonal flora translocation, A932 verapamil pharmacokinetics and pharmacody- els of high-density lipoprotein cholesterol, 767 Antipsychotic Agents. See also specific agents namics, 1083 renal and limb vasodilation during acute beta- iloperidone, 713 Breast-Feeding adrenoreceptor blockade with indenolol, 176 Antipyretic Agents alteration of nursing infant's hepatic drug metab- serotonin and serotonin antagonism in cardio- ibuprofen, A929 olizing pattern by chronic maternal therapy, vascular and noncardiovascular disease, 541 naproxen, A929 1025 Cefoperazone Antipyrine BRL 49653C pharmacokinetics, 250 aging effects on clearance, 895 pharmacokinetics, A926 Ceftizoxime antipyrine metabolism and acetylation pheno- Bupropion pharmacokinetics, 1046 type in health and chronic liver diseases, 615 pharmacokinetics, 876 in trauma celiotomy, 1046 1212 Celiotomy immunopharmacodynamic studies in patients diprafenone hydrochloride and propranolol hy- ceftizoxime in trauma celiotomy, 1046 awaiting renal transplantation, 967 drochloride, 721 Central Nervous System. See also Antipsychotic pharmacokinetics, 681 famotidine and theophylline, 529 Agents Cytochrome P450 Enzymes 5-fluorouracil and methotrexate, 1156 alosetron effects on haloperidol pharmacokinet- inhibition by monoclonal and polyclonal anti- fosinopril and hydrochlorothiazide, A924 ics in schizophrenia, 202 bodies, A925 gentamicin and verapamil, 196 mitoxantrone cardiotoxicity in relapsing remit- venlafaxine metabolism and, A936 glyburide and orlistat, 521 ting multiple sclerosis, 627 Cytokines haloperidol and alosetron, 202 xanomeline tartrate safety and efficacy in Alz- ciprofloxacin and, A924 hydrochlorothiazide and fosinopril, A924 heimer’s disease, 800 Cytotoxic Drugs hydrochlorothiazide and losartan, 1200 CGP 36 742 tamoxifen with for non-Hodgkin's lymphoma, lidocaine and adrenaline, 426 pharmacokinetics, A922 A936 losartan and hydrochlorothiazide, 1200 Children. See Pediatrics losartan and warfarin, 1008 Chlorthalidone methotrexate and 5-fluorouracil, 1156 interaction with ramipril, 1150 Death N-acetylprocainamide and para-aminobenzoic ramipril decrease of loss of magnesium and po- sudden unexplained death in epilepsy, 573, A940 acid, 902 tassium in hypertension induced by, 1150 Depression. See also Antidepressant Agents; spe- nefazodone and dextromethorphan, A925 Cholesterol cific agents nefazodone and propranolol, 1109 ibuprofen cholesterol isomers and, A939 bupropion pharmacokinetics in elderly patients nefazodone and warfarin, 730 phenytoin effects on plasma high-density lipo- with, 876 orlistat and digoxin, 840 protein cholesterol levels in men with low lev- Dermatology orlistat and glyburide, 521 els of high-density lipoprotein cholesterol, 767 nonsteroidal anti-inflammatory drugs in, A932 para-aminobenzoic acid and N-acetylprocai- terazosin effects in patients with diabetes melli- Dextromethorphan namide, 902 tus and hypertension and, A934 interaction with nefazodone, A925 para-aminobenzoic acid and procainamide, 902 Chronic Disease Dezocine procainamide and para-aminobenzoic acid, 902 clinical trials in, 594 pharmacokinetics, 398 propranolol and nefazodone, 1109 Chronic Obstructive Pulmonary Disease Diabetes Mellitus propranolol hydrochloride and diprafenone hy- famotidine and theophylline interaction in, 529 antihypertensive therapy in, 73 drochloride, 721 Cibenzoline glyburide protein binding and effect of albumin ramipril and chlorthalidone, 1150 in prevention of paroxysmal atrial arrhythmias, glycation in, 739 rivastatin and warfarin, 306 471 terazosin effects on glycemic control, cholesterol, sparfloxacin and theophylline, A936 Ciprofloxacin and microalbuminuria in patients with diabe- sumatriptan succinate and butorphanol tartrate cytokine production and tacrolimus and, A924 tes mellitus and hypertension and, A934 nasal spray, 432 Cirrhosis Diazepam tacrine and warfarin, 526 galactose single point method as measure of re- interaction with venlafaxine, 410 tetanus-diphtheria vaccine and tetanus immune sidual liver function, 250 Digoxin globulin, 420 Citrus Fruits interaction with carbimazole, A922 tetanus immune globulin and tetanus-diphtheria tandem mass spectrometry for in vivo flavanone interaction with orlistat, 840 vaccine, 420 evaluation and, A923 Dihematoporphyrin theophylline and famotidine, 529 Clavulanic Acid pharmacokinetics, A936 theophylline and sparfloxacin, A936 ticarcillin/clavulanic acid dese recommenda- Diltiazem venlafaxine and diazepam, 410 tions for infants and children, 658 clinical experience in hypertension, 220 verapamil and gentamicin, 196 Clinical Pharmacology diltiazem ER for severe hypertension, A923 warfarin and losartan, 1008 effective half-life in, 763 dose-ranging study of diltiazem for stable angina, warfarin and nefazodone, 730 experience-based teaching of therapeutics and 189 warfarin and rivastatin, 306 clinical pharmacology of antiepileptic drugs, gender differences in exercise and recovery warfarin and tacrine, 526 573, A940 blood pressures in normal volunteers given dil- DuP 996. See Linopirdine surrogate biochemical markers and, 441 tiazem, 1144 DuP 753/MK 954. See Losartan teaching clinical pharmacology of antiepileptic pharmacokinetics, A924 drugs, 1120, A940 Diprafenone hydrochloride teaching pharmacology in the informatics age, interaction with propranolol hydrochloride, 721 Editorial Disopyramide presidential address, 333 A940 food and absorption and disposition profiles of, The Tradition of Scientific Publication, 1119 training utilizing telecommunication technol- ogy, A934 A921 Education protein binding, 510 Clinical Pharmacology Problem Solving (CPPS) Clinical Pharmacology Problem Solving Unit DMP 450 Unit, 1120 CPPS unit on antiepileptic drugs, 1120 pharmacokinetics, A933 clinical therapeutic approach for teaching health Clinical Trials DMP 504 care professionals about drug-induced disease, in chronic diseases, 594 safety and tolerance, A934 A940 Congestive Heart Failure Dolasetron computer-based system of instruction on new calcium antagonist therapy for, 443 dose-ranging safety evaluation of, 713 perspectives in prevention and treatment of fosinopril pharmacodynamics in, 785 Drug Development asthma, A933 mexiletine effects on left ventricular contractil- bidisomide, A921 experience-based teaching of therapeutics and ity in, 478 concentration-guided strategies, 1136 clinical pharmacology of antiepileptic drugs, Cordiachromene A disopyramide, A921 573, A940 antiinflammatory mechanism, 298 surrogate biochemical markers, 464 student feedback comments on examinations, Cortisol Drug-Induced Disease A940 clinical therapeutic approach for teaching health survey results of POPS use, 117 losartan effects on response to adrenocortico- care professionals about, A940 teaching clinical pharmacology of antiepileptic tropic hormone, 776 Drug Interactions drugs, A940, 1120 suppression after oral administration of fluocor- adrenaline and lidocaine, 426 teaching pharmacology in the informatics age, tolone, A926 Critical Care abluotsoertprhoan noaln d thaartlroapteer idnoals,a l 20s2p ray and sumatrip- traAi9n4i0ng utilizing telecommunication technol- high-grade nucleoside transport inhibition stim- tan succinate, 432 ogy, A934 Crouhlant’isn g Divsenetaislea tion, 357 carbimazole and digoxin, A922 EElldeecrtlryo cPaartdieinotgsr.a pSheye Geriatrics cyclosporine pharmacokinetics in, 681 chlorthalidone and ramipril, 1150 amlodipine effects in black patients with very se- Cyclosporine dextromethorphan and nefazodone, A925 vere hypertension, 1052 concentration-guided strategies in development diazepam and venlafaxine, 410 Electroencephalography for transplantation, 1136 digoxin and carbimazole, A922 psychological performance parameters under cyclosporine A pharmacokinetics, 865 digoxin and orlistat, 840 scopolamine correlated with, A922 1213 EMLA Cream Food Heart. See Left Ventricular Function efficacy for venipuncture, A924 avortavastatin bioavailability and, 990 Heart Failure. See also Congestive heart failure Enalapril bidisomide absorption and disposition profiles, lisinopril for, 673 adverse effects, 484 A921 Helicobacter Pylori for severe hypertension, A923 bidisomide plasma level, A921 gastrointestinal disease and, 647 Endocrinology disopyramide absorption and disposition profiles, impaired gastric electrical rhythm in Helico- losartan effects on response of cortisol and aldo- A921 bacter pylori infected subjects, A921 sterone to adrenocorticotropic hormone, 776 iloperidone pharmacokinetics and, 713 Hemodialysis pinacidil effects on insulin release, 291 isosorbide-5-mononitrate bioavailability and, bepridil plasma protein binding and, 137 subcutaneous octreotide infusion for acromeg- 151 carboplatin pharmacokinetics in cervical cancer aly, 59 norverapamil pharmacokinetics and pharmaco- with ureteric obstruction before, during, and Enzymes dynamics, 1083 after, 1003 enzyme kinetic modeling as tool in identifying reduced dietary fat absorption induced by orlis- gabapentin disposition in anuric subjects on, 622 metabolic pathways, A926 tat and digoxin pharmacokinetics, 840 lansoprazole pharmacokinetics and, 815 Epidemiology. See Pharmacoepidemiology retinoid pharmacokinetics and, A930 Hemostasis Epilepsy. See also Antiepileptic Agents; specific sibutramine metabolite bioavailability and, A927 nonsteroidal anti-inflammatory drug effects on, agents verapamil bioequivalence and, 163 carbamazepine and carbamazepine-10 bound se- verapamil pharmacokinetics and pharmacody- Heparin rum concentration prediction after polyther- namics and, 1083 in antithrombotic therapy, 1031 apy in, 995 Fosinopril ardeparin pharmacokinetics, 1194 sudden unexplained death in, 573, A940 interaction with hydrochlorothiazide, A924 Hepatic Function Eptastigmine pharmacodynamics, 785 alteration of nursing infant’s hepatic drug metab- pharmacodynamics, 285 pharmacokinetics, 145 olizing pattern by chronic maternal therapy, pharmacokinetics, 285 Fosinoprilat 1025 Erectile Dysfunction pharmacokinetics, 145 antipyrine metabolism and acetylation pheno- alprostadil safety and efficacy in, A937 type in health and chronic liver diseases, 615 Estrogens Gabapentin fosinopril and fosinoprilat in hepatic impair- benefit/risk of estrogen therapy in cardiovascu- pharmacokinetics, 622 ment, 145 lar disease, 11S Gastrointestinal System galactose single point method as measure of re- cardiovascular actions and cardioprotective ben- cyclosporine pharmacokinetics in Crohn’s Dis- sidual liver function, 250 efits of replacement therapy in postmeno- ease, 681 head-down tilt effects on lidocaine pharmacoki- pausal women, 314 Helicobacter pylori and gastrointestinal disease, netics as probe to evaluate hepatic blood flow, estarnodg epnr etvheenrtaipoyn foofr osptoesotpmoreonsoipsa,u s2aSl symptoms imp6a47i red gastric electrical rhythm in Helico- tra6n9d7o lapril pharmacokinetics in fatty liver dis- future therapeutic developments, 25S bacter pylori infected subjects, A921 ease, A922 . pharmacokinetic and pharmacologic variation methyldopa presystemic gut metabolism, 275 verapamil pharmacokinetics in fatty liver dis- between estrogen products, 18S oral medication delivery system for famotidine, ease, A922 Exercise High Altitude gender differences in exercise and recovery pra3v6a2s tatin absorption in healthy subjects, 142 meperidine and normeperidine excretion upon blood pressures in normal volunteers given dil- Gender exposure to, A931 tiazem, 1144 gender differences in exercise and recovery meperidine pharmacokinetics upon exposure to, propranolol pharmacokinetics in young and el- blood pressures in normal volunteers given dil- A931 derly adults and, 885 tiazem, 1144 HIV. See Human Immunodeficiency Virus EXP3174 Genetics. See Pharmacogenetics HP 749. See Bespiridine Hydrochloride plasma protein binding, 515 Gentamicin HP 873. See Iloperidone interaction with verapamil, 196 H,-Receptor Antagonists Famotidine Geriatrics cardiovascular effects, 107 interaction with theophylline, 529 bupropion pharmacokinetics in elderly patients 5-HT, Receptors oral medication delivery system for, 362 with depression, 876 pharmacologic and therapeutic aspects of, 845 Fatty Liver Disease CGP 36 742 pharmacokinetics and, A922 Human Immunodeficiency Virus trandolapril pharmacokinetics in, A922 flucloxacillin in elderly hospitalized patients, 31 pentamidine pharmacokinetics in prophylaxis of verapamil pharmacokinetics in, A922 indapamide for hypertension in elderly patients, Pneumocystis carinii pneumonia in patients Felodipine infected with, 1166 pharmacokinetics, A938 lac4k5 of effect of aerobic exercise on propranolol Hydrochlorothiazide vasodilating properties, A938 pharmacokinetics in young and elderly adults interaction with fosinopril, A924 Fenoldopam interaction with losartan, 1200 pphhaarrmmaaccookdiynnetaimcisc,s , A9A3923 2 linavonopdli,ur ndt8ie8ne5er s,i n 2h2e althy young adults and elderly lows-iodno,s e1,8 2w ith low-dose bisoprolol for hyperten- Fentanyl pharmacokinetics, 1200 pharmacokinetics, 159 sibtiuetnrtas,m iAn9e2 8p harmacokinetics and in elderly pa- Hydromorphone FtFllaeanofcvd,aae iAnmn9o i2ndm3eea s s s spectrometry for in vivo evaluation Ggiln!tyygebblruyuarcrciaitdtdieioeo n n p rwiointt edhii nao brelbtiiesntsda,ti ,n 7g35 92 1a nd effect of albumin pHpHhhyyaapdrrermmroaatmcceooonkrksiipinnoheenott.nii ecc-ss,3,S -eG33el77 ucualrsoon ideA ntihypertensive in prevention of paroxysmal atrial arrhythmias, Agents; specific agents Granulocyte-Macrophage Colony Stimulating 471 Factor amlodipine and benazepril monotherapy com- Fplhuacrlmoaxcaockiilnleitni cs, 31 zidovudine pharmacokinetics and, 856 ptaemriecd hwyipthe rtaemnlsoidoinp,i n1e0 60p lus benazepril in sys- Fluocortolone amlodipine effects in black patients with very se- pharmacodynamics, A926 Haloperidol vere hypertension, 1052 pharmacokinetics, A926 interaction with alosetron, 202 angiotensin-converting enzyme inhibitor ther- 5-Fluorouracil intra- and interethnic variability in reduced hal- apy for, 337 interaction with methotrexate, 1156 operidol to haloperidol ratios, 128 diltiazem for, 220 Fluoxetine pharmacokinetics, 202 enalapril and diltiazem ER compared in severe enantiomers of, A938 risperidone compared with for schizophrenia, hypertension, A923 pharmacokinetics, 17 A937 fenoldopam pharmacodynamics in moderately Flurbiprofen Headaches severe hypertension, A932 pharmacodynamics, A925 ibuprofen and acetaminophen for muscle-con- indapamide therapy in elderly patients with, 45 pharmacokinetics, A925 traction headache, A929 insulin resistance in systemic hypertension, 943 Fluticasone Heart. See Arrhythmias; Cardiovascular Sys- isradipine and enalapril adverse effects com- input rate into systemic circulation, A927 tem; Congestive heart failure pared, 484 1214 isradipine-CR for sustained blood pressure con- Leg Cramps Moexipril trol, 239 quinine for, 588 efficacy assessment, 233 management of hypertensive urgencies and Leukotriene B, verapamil versus, for mild to moderate hyperten- emergencies, 747 inhibition in healthy males, A930 sion, 794 moexipril versus verapamil for mild to moderate Lidocaine Monoclonal Antibodies hypertension, 794 head-down tilt effects on lidocaine pharmacoki- cytochrome P450 enzyme inhibition by, A925 ramipril decrease of chlorthalidone-induced loss netics as probe to evaluate hepatic blood flow, Moricizine of magnesium and potassium in, 1150 697 pharmacokinetics, 1016 terazosin effects on glycemic control, cholesterol, interaction with adrenaline, 426 Morphine and microalbuminuria in patients with diabe- pharmacokinetics, 426 in cancer pain, 666 tes mellitus and hypertension and, A934 Linopirdine effect on postoperative pain following total ab- Hypogonadism pharmacokinetics, 17 dominal hysterectomy or myomectomy, A927 testosterone pharmacokinetics in, A923 Lipids. See also Orlistat pharmacokinetics, 499 ACE therapy in renal disease and, 87 Multiple Sclerosis Ibuprofen phenytoin effects on plasma high-density lipo- mitoxantrone cardiotoxicity in relapsing remit- antipyretic efficacy in upper respiratory illness, protein cholesterol levels in men with low lev- ting multiple sclerosis, 627 A929 els of high-density lipoprotein cholesterol, 767 cholesterol isomers and, A939 reduced dietary fat absorption induced by orlis- N-Acetylprocainamide disposition of stereoisomers in presence of non- tat and digoxin pharmacokinetics, 840 interaction with para-aminobenzoic acid, 902 linear plasma protein binding, A939 5-Lipogenase Inhibitor 6-8-Naltrexol efficacy with pseudoephedrine for nasal conges- leukotriene B, inhibition and, A930 pharmacokinetics, A933 tion, A929 Lisinopril Naltrexone for muscle-contraction headache, A929 for heart failure, 673 morphine bioequivalence, 499 for orthodontic pain in children, A929 Liver. See Hepatic Function pharmacokinetics, A933 pharmacodynamics, A925 Lornoxicam Naproxen pharmacokinetics, A925 analgesic effect after surgical removal of mandib- antipyretic efficacy in upper respiratory illness, tolerance and efficacy of, A938 ular third molars, 606 A929 lloperidone Losartan Nasal Congestion pharmacokinetics, 713 effects on response of cortisol and aldosterone to ibuprofen efficacy with pseudoephedrine for na- Immunology adrenocorticotropic hormone, 776 sal congestion, A929 immunopharmacodynamic studies of cyclospor- interaction with hydrochlorothiazide, 1200 Nefazodone ine in patients awaiting renal transplantation, interaction with warfarin, 1008 interaction with dextromethorphan, A925 967 pharmacokinetics, 1200 interaction with propranolol, 1109 Indapamide plasma protein binding, 515 interaction with warfarin, 730 for mild to moderate hypertension in elderly pa- Lovastatin pharmacodynamics, 1109 tients, 45 early restenosis and, 599 pharmacokinetics, 830, 974, 1109 Indenolol Nicotine renal and limb vasodilation during acute beta- Magnesium pharmacokinetics, 493, 985 adrenoreceptor blockade with, 176 ramipril decrease of chlorthalidone-induced loss Nisoldipine Infants. See Pediatrics in hypertension, 1150 antianginal and antiischemic efficacy in chronic Infectious Diseases Marfan Syndrome stable angina, 780 ceftizoxime in trauma celiotomy, 1046 atenolol absorption pharmacokinetics in, 268 Nitroglycerin pentamidine pharmacokinetics in prophylaxis of Mass Spectrometry pharmacokinetics, 390 Pneumocystis carinii pneumonia in patients dual selective detection of stable isotope labeled Nizatidine infected with human immunodeficiency virus, drug in whole urine using, A935 pharmacokinetics, 1071 1166 selective detection of stable isotope labeled drug Nonsteroidal Anti-Inflammatory Drugs. See also Insulin in serum using, A935 specific agents insulin resistance in systemic hypertension, 943 tandem mass spectrometry for in vivo flavanone in dermatology, A932 pinacidil effects on release of, 291 evaluation and, A923 platelet function and systemic hemostasis and, Interferon Alfa-2a Medical Delivery Systems 209 pharmacokinetics, 281 oral medication delivery system for famotidine, Norepinephrine Ischemia 362 phentolamine antagonism of hand vein constric- antianginal and antiischemic efficacy of nisoldip- Menopause. See Estrogens tion induced by, 170 ine in chronic stable angina, 780 Meperidine Normeperidine Isosorbide-5-Mononitrate pharmacokinetics, A931 urinary excretion of, A931 pharmacokinetics, 151 for sickle cell painful episodes, A937 Norverapamil Isotretinoin urinary excretion of, A931 pharmacodynamics, 1083 systemic absorption of isotretinoin cream, A930 Metabolism pharmacokinetics, 1076, 1083 Isradipine enzyme kinetic modeling as tool in identifying Nucleosides adverse effects, 484 metabolic pathways, A926 high-grade nucleoside transport inhibition stim- Isradipine-CR venlafaxine, A936 ulating ventilation, 357 sustained blood pressure control, 239 Metformin pharmacokinetics, 1094 Methodology Ketorolac clinical trials in chronic diseases, 594 Obesity ketorolac adenylate in chiral inversion of, A939 galactose single point method as measure of re- sibutramine pharmacokinetics and, A928 for sickle cell painful episodes, A937 sidual liver function, 250 Octreotide Kidney. See Renal Disease; Renal Function Methotrexate for acromegaly, 59 interaction with 5-fluorouracil, 1156 Oncology Lactation Methyldopa adrenalin and lidocaine interaction in pancreatic alteration of nursing infant’s hepatic drug metab- pharmacokinetics, 275 neoplasia, 426 olizing pattern by chronic maternal therapy, Mexiletine carboplatin pharmacokinetics in cervical cancer 1025 left ventricular contractility in congestive heart with ureteric obstruction before, during, and Lamivudine failure and, 478 after hemodialysis, 1003 pharmacokinetics, 1174 Microalbuminuria hydromorphone and hydromorphone-3-glucuro- Lansoprazole terazosin effects in patients with diabetes melli- nide and, 37 pharmacokinetics, 815 tus and hypertension and, A934 methotrexate modulation by 5-fluorouracil, 1156 Left Ventricular Function Misoprostol morphine for cancer pain, 666 amlodipine effects in black patients with very se- pharmacokinetics, 384 phenylbutyrate, phenylacetate, and phenylacet- vere hypertension, 1052 Mitoxantrone ylglutamine disposition, 368 mexiletine effects on left ventricular contractil- cardiotoxicity in relapsing remitting multiple tamoxifen with cytotoxic drugs for non-Hodg- ity in congestive heart failure, 478 sclerosis, 627 kin’s lymphoma, A936 Organ Transplantation bupropion, 876 Phenylacetylglutamine concentration-guided strategies in development carbamazepine, 995 disposition, 368 for transplantation, 1136 carbamazepine-10, 995 Phenylbutyrate immunopharmacodynamic studies of cyclospor- carboplatin, 1003 disposition, 368 ine in patients awaiting renal transplantation, cefoperazone, 250 Phenytoin 967 ceftizoxime, 1046 effects on plasma high-density lipoprotein cho- Orlistat CGP 36 742, A922 lesterol levels in men with low levels of high- interaction with digoxin, 840 cyclosporine, 681 density lipoprotein cholesterol, 767 interaction with glyburide, 521 cyclosporine A, 865 pharmacokinetics, A928 pharmacokinetics, 1103 dezocine, 398 Pinacidil Osteoporosis dihematoporphyrin, A936 insulin release in healthy volunteers and, 291 estrogen therapy for prevention of, 2S diltiazem, A924 Piroxicam Oxprenolol DMP 450, A933 intradermal toxicity of, A934 pharmacokinetics, A939 effective half-life in clinical pharmacology, 763 P-450 Isoforms eptastigmine, 285 cocktail strategy for, 655 estrogens, 18S Platelet Function Pain. See also Analgesics; specific agents felodipine, A938 nonsteroidal anti-inflammatory drug effects on, dezocine pharmacokinetics and, 398 fenoldopam, A932 209 ibuprofen and acetaminophen for orthodontic fentanyl, 159 Pneumocystis Carinii Pneumonia pain in children, A929 first-time-in-human dose selection, 957 pentamidine pharmacokinetics in prophylaxis morphine effect on postoperative pain following flucloxacillin, 31 of, 1166 total abdominal hysterectomy or myomec- fluocortolone, A926 Polyclonal Antibodies tomy, A927 fluoxetine, 17 cytochrome P450 enzyme inhibition by, A925 Para-aminobenzoic acid flurbiprofen, A925 POPS. See Patient-Oriented Problem-Solving interaction with N-acetylprocainamide, 902 fosinopril, 145 Potassium interaction with procainamide, 902 fosinoprilat, 145 ACE therapy in renal disease and, 87 Patient-Oriented Problem-Solving gabapentin, 622 ramipril decrease of chlorthalidone-induced loss survey results of use, 117 haloperidol, 202 in hypertension, 1150 Pediatrics hydrochlorothiazide, 1200 Pravastatin alteration of nursing infant’s hepatic drug metab- hydromorphone, 37 pharmacokinetics, 142 olizing pattern by chronic maternal therapy, hydromorphone-3-glucuronide, 37 Predictive Testing 1025 ibuprofen, A925 role ofi n vivo and in vitro testing, A931 cyclic antidepressant toxicity, 343 iloperidone, 713 Procainamide eutectic mixture of local anesthetics for pro- interferon alfa-2a, 281 interaction with para-aminobenzoic acid, 902 longed subcutaneous drug administration, 295 isosorbide-5-mononitrate, 151 Propranolol glyburide protein binding and effect of albumin lamivudine, 1174 interaction with diprafenone hydrochloride, 721 glycation in diabetes, 739 lansoprazole, 815 interaction with nefazodone, 1109 ibuprofen and acetaminophen for orthodontic lidocaine, 426 pharmacodynamics, 1109 pain, A929 linopirdine, 22 pharmacokinetics, 374, 885, 1109 moricizine pharmacokinetics, 1016 losartan, 1200 Protein Binding ticarcillin/clavulanic acid dose recommenda- meperidine, A931 bepridil, 137 tions for infants and children, 658 metformin, 1094 carbamazepine and carbamazepine-10 bound se- valproate clearance value estimation in children, methyldopa, 275 rum concentration prediction after polyther- 1020 misoprostol, 384 apy in epilepsy, 995 Pentamidine moricizine, 1016 disopyramide, 510 pharmacokinetics, 1166 morphine, 499 EXP3174, 515 Peptic Ulcer Disease 6-6-naltrexol, A933 glyburide protein binding and effect of albumin nizatidine pharmacokinetics in, 1071 naltrexone, A933 glycation in diabetes, 739 Pharmacodynamics nefazodone, 830, 974, 1109 ibuprofen stereoisomers distribution in presence aspirin, 1181 nicotine, 985 of nonlinear plasma protein binding, A939 atenolol, 807 nicotine transdermal systems, 493 losartan potassium, 515 eptastigmine, 285 nitroglycerin, 390 Proteinuria fenoldopam, A932 nizatidine, 1071 ACE therapy in renal disease and, 87 fluocortolone, A926 noncompartmental analysis of pharmacokinetic PSC833 flurbiprofen, A925 data after oral and intravenous administration, pharmacokinetics, A937 fosinopril, 785 A925 Pseudoephedrine ibuprofen, A925 norverapamil, 1076 efficacy with ibuprofen for nasal congestion, immunopharmacodynamic studies of cyclospor- orlistat, 1103 A929 ine in patieAts awaiting renal transplantation, oxprenolol, A939 pharmacokinetics, 259 967 pentamidine, 1166 Psoriasis nefazodone, 1109 phenytoin, A928 cyclosporine A pharmacokinetics in, 865 norverapamil, 1083 pravastatin, 142 propranolol, 1109 propranolol, 374, 885, 1109 Quinine triamcinolone acetonide, 1187 PSC833, A937 for leg cramps, 588 verapamil, 1083 pseudoephedrine, 259 Pharmacoepidemiology retinoids, A930 Radiofrequency Ablation aging effects on antipyrine clearance, 895 scopolamine, A922 inability to tolerate long term drug therapy as in- intra- and interethnic variability in reduced hal- sibutramine, A927, A928 dication for radiofrequency catheter ablation operidol to haloperidol ratios, 128 sotalol, A928 of supraventricular arrhythmias, A927 Pharmacogenetics tamoxifen, A936 Ramipril antipyrine metabolism and acetylation pheno- testosterone, A923 decrease of chlorthalidone-induced loss of mag- type in health and chronic liver diseases, 615 trandolapril, A922 nesium and potassium in hypertension by, Pharmacokinetics triamcinolone acetonide, 302, 1187 1150 amitriptyline, 17 venlafaxine, 404 Renal Disease ardeparin, 1194 verapamil, 163, A922, 1076 ACE therapy in, 87 aspirin, 1181 zidovudine, 856 bepridil pharmacokinetics in, 379 atenolol, 268, 807 Phentolamine dosing of antihypertensive agents in renal in- atorvastatin, 990 antagonism of norepinephrine-induced hand sufficiency, 73 beprid1i37l, ,37 9 vein constriction, 170 immunopharmacodynamic studies of cyclogpor- bespiridine hydrochloride, 688 Phenylacetate ine in patients awaiting renal transplantation, BRL 49653C, A926 disposition, 368 967 1216 individualized approach to hypertension in, 98 Sumatriptan Succinate Transplantation. See Organ Transplantation Renal Function. See also Renal Disease interaction with butorphanol tartrate nasal Trauma ACE therapy in renal disease, 87 spray, 432 ceftizoxime in trauma celiotomy, 1046 antihypertensive agents in diabetic patients, 73 Surrogate Biochemical Markers Triamcinolone Acetonide dosing of antihypertensive agents in renal in- clinical pharmacology and, 441 pharmacokinetics, 302, 1187 sufficiency, 81 development, 464 pharmacodynamics, 1187 individualized approach to hypertensive pa- Trimipramine tients with renal disease, 98 Tacrine enantiomers of, A938 metformin pharmacokinetics and, 1094 interaction with warfarin, 526 Tyramine misoprostol pharmacokinetics, 384 Tacrolimus adverse effects, 633 over-the-counter analgesics and, 454 ciprofloxacin and, A924 renal and limb vasodilation during acute beta- Tamoxifen Vaccines adrenoreceptor blockade with indenolol, 176 with cytotoxic drugs for non-Hodgkin’s lym- tetanus-diphtheria vaccine and tetanus immune symposium from 1993 annual meeting of Ameri- phoma, A936 globulin interaction, 420 can College of Clinical Pharmacology, 72 pharmacokinetics, A936 Valproate verapamil effects on nephrotoxic potential of Telec ication clearance value estimation in children, 1020 gentamicin, 196 training utilizing, A934 Valsartan Respiratory Illness Terazosin pressor response to angiotensin-II in healthy ibuprofen and naproxen antipyretic efficacy in, glycemic control, cholesterol, and microalbu- males and, A930 A929 minuria in patients with diabetes mellitus and Vasodilation Retinoids hypertension and, A934 felodipine, A938 pharmacokinetics, A930 Testosterone Venipuncture Risperidone pharmacokinetics, A923 EMLA cream efficacy for, A924 haloperidol compared with for schizophrenia, Tetanus-Diphtheria Vaccine Venlafaxine A937 interaction with tetanus immune globulin, 420 interaction with diazepam, 410 Rivastatin Tetanus Immune Globulin metabolism of, A936 interaction with warfarin, 306 interaction with tetanus-diphtheria vaccine, 420 pharmacokinetics, 404 Theophylline Venodilation Schizophrenia interaction with famotidine, 529 amrinone and theophylline venodilatory effects alosetron effects on haloperidol pharmacokinet- interaction with sparfloxacin, A936 compared, 1067 ics, 202 venodilatory effect compared with amrinone, Ventilation haloperidol and risperidone compared for, A937 1067 high-grade nucleoside transport inhibition stim- Scopolamine Ticarcillin ulating, 357 pharmacokinetics, A922 ticarcillin/clavulanic acid dose recommenda- Verapamil Serotonin tions for infants and children, 658 interaction with gentamicin, 196 in cardiovascular and noncardiovascular dis- Time low once-daily doses for mild hypertension, 52 ease, 541 norverapamil pharmacokinetics and pharmaco- moexipril versus, for mild to moderate hyperten- Sibutramine dynamics, 1083 sion, 794 pharmacokinetics, A927, A928 verapamil pharmacokinetics and pharmacody- pharmacodynamics, 1083 Sickle Cell Anemia namics, 1083 pharmacokinetics, 163, A922, 1076, 1083 ketorolac and meperidine compared for painful Tooth Extraction Vitamin A episodes, A937 lornoxicam analgesic effect after surgical re- retinoid pharmacokinetics and, A930 Side Effects. See Adverse Effects; specific drugs moval of mandibular third molars, 606 SNX-111 Toxicity Warfarin safety and tolerability study, A933 anthracycline cardiotoxicity, A935 interaction with losartan, 1008 Sotalol cyclic antidepressant toxicity in children and ad- interaction with nefazodone, 730 pharmacokinetics, A928 olescents, 343 interaction with rivastatin, 306 Sparfloxacin mitoxantrone cardiotoxicity in relapsing remit- interaction with tacrine, 526 interaction with theophylline, A936 ting multiple sclerosis, 627 Stereoselectivity piroxicam, A934 Xanomeline Tartrate verapamil and norverapamil enantiomer phar- verapamil effects on nephrotoxic potential of safety and efficacy in Alzheimer’s disease, 800 macokinetics, 1076 gentamicin, 196 Sudden Death Trandolapril Zidovudine sudden unexplained death in epilepsy, 573, A940 pharmacokinetics, A922 pharmacokinetics, 856

ebook img

Journal of Clinical Pharmacology 1995: Vol 35 Index PDF

9 Pages·1995·2.7 MB·English
by  
#periodicals #sim_microfilm #pub_journal-of-clinical-pharmacology
Save to my drive
Quick download
Download
Upgrade Premium
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.

Preview Journal of Clinical Pharmacology 1995: Vol 35 Index

Author Index, Volume 35 (1995) Abdelwahab W, 747 Brecher MB, 713 Davis S, 295 Ford NF, 145, 785 Abernathy T, 588 Brion JD, 298 De Castro S, 627 Forrest A, 807 Abernethy DR, 794 Bruera E, 666 de Vries A, 357 Foster RT, 1076 Affrime M, 856 Bryzinski BS, 182 Dean R, 688 Fowles RE, 673 Affrime MB, 151 Buckley SJ, 1144 Dee CM, 721 Fox AAL, 233, 794 Albrink MH, 1046 Bugge C, 606 Del Rosso A, 176 Fozailoff A, 943 Alemayehu D, 182 Bulle T, 673 Derendorf H, 302, 885, 1187 Franco J, 856 Alexander S, 673 Burris JF, 182, 337 Desiraju RK, 379 Freeman R, 314 Alfurayh O, 1003 Bury M, 821 Dett C, 856 Freundlich NL, 521, 840 Ali H, 615 Deutsch PJ, 1008 Frishman W, 314, 747 Almar MM, 895 Caille P, 633 DeVane CL, 876 Frishman WH, 182, 541, Alpert BS, 268 Calvo B, 426 Dhaliwal HS, 37 943, 1060 Altieri LP, 876 Campbell NRC, 275 D’Hautefeuille B, 471 Fromell G, 189 Al-Uzri A, 856 Capra NL, 1200 Di ZS, 510 Fruncillo R, 1194 Amer M, 1003 Carter BL, 81 Dies F, 800 Fruncillo RJ, 404 Amidon GL, 374 Cartoni D, 627 DiLea C, 957 Fujii I, 995 Archer S, 189 Causey D, 985 Dileo EM, 688 Fujimura A, 776, 1067 Armand P, 633 Cavanaugh JM, 815 Dillon KR, 1046 Fulmor IE, 730, 785, 1109 Arns W, 1136 Cediel M, 885 Dingemanse J, 821 Funaro S, 627 Arora S, 840 Cerimele BJ, 170 Dockens RC, 730 Atkinson L, 1083 Chaikin PC, 730 Dominguez-Gil A, 426 Gad A, 17 Aweeka FT, 856, 967 Chaleby K, 17 Donsky J, 295 Gaillard AWK, 821 Awni WM, 379 Chan K, 390 Dossing M, 615 Galia EF, 1187 Chang C-L, 250 Driver MR, 505 Gambertoglio JG, 856, 967 Babul N, 37, 666 Chang C-T, 865 Du Plooy WJ, 244 Gammans RR, 974 Babuty D, 471 Chang W-H, 128 Duerr H, 721 Garcia-Ortega E, 426 Bachmann K, 529 Charles B, 31 Durrieu G, 633 Garland WT, 780 Bakris GL, 72, 073 Charnick S, 865 d’Uscio CH, 967 Garner DM, 22 Barbhaiya RH, 432, 830, Chautsane Z, 1052 Duursema L, 306 Garnett WR, 526 974 Chen H, 128 Dye D, 259 Garovoy MR, 967 Barclay KD, 1144 Chen S-Y, 182 Garzarella L, 885 Barr WH, 721 Chi E, 713 Ebel DL, 362 Gascon AR, 426 Barth J, 302, 1187 Chiang J, 1094 Ebihara A, 776 Gasperini C, 627 Bastian HL, 606 Chiang S, 1194 Eff J, 189 Gath J, 31 Batlle D, 87 Chiang ST, 404, 410 Eggers H, 1103 Gavish D, 599 Battle M, 763 Chopamba A, 1052 Eisner GM, 484 Gibaldi M, 647, 1031 Beigel Y, 599 Chow MSS, 11S, 1S Elder CA, 865 Gieschke R, 821 Beller B, 673 Christ DD, 515 Eldon MA, 622 Gil A, 420 Benedek IH, 1181 Christopher D, 151 Eller M, 493 Giles TD, 673 Benedict CR, 705 Chrysant SG, 189, 239, 1060 Elliott WJ, 98 Giustina A, 285 Benet LZ, 967, 1094 Cilla DD, 990 El-Yazigi A, 17, 615, 1003 Glasser SP, 780 Beni S, 627 Cipriano A, 390 Erdmann M, 302, 1187 Goerdt C, 767 Benslimane AF, 298 Cleophas TJM, 594 Ernst P, 615 Goldberg MJ, 170 Berger ML, 362 Codispoti J, 45 Ersboll BK, 606 Goldberg MR, 1008, 1200 Berkovitch M, 295 Cogan MG, 1094 Ezzat S, 59 Golden JA, 1166 Berlin I, 633 Cohen A, 865 Goldenheim PD, 499 Betrabet SS, 1025 Cohen M, 239 Fagan TC, 52 Goldfarb AL, 196 Bhatti MM, 1076 Cohen RI, 398 Fainaru M, 599 Gonzalez A, 420 Bisi G, 176 Colburn WA, 441, 464, 655 Fainsinger R, 666 Gonzalez-Gallego J, 895 Bittar N, 780 Colfer H, 673 Ferdinand K, 45 Gonzalez-Sastre M, 895 Bjornsson TD, 362, 1008 Collins JF, 170 Ferdinand KC, 52 Goodman AM, 1094 Bleske BE, 374 Conte JE, 1166 Fiddes R, 189 Gorsline J, 259, 493, 985 Blumer JL, 658 Cornac A, 697 Figg WD, 368 Graff A, 1060 Bockbrader HN, 622 Cramer M, 705 Fillit H, 25S Grandy RP, 499 Bootsma G, 357 Curry C, 45 Fisher MB, 673 Grasing K, 713 Borin MT, 505 Cutler DL, 856 Fiske WD, 22 Graves JE, 885 Borzak S, 902 Cutler NR, 189, 800 Fitoussi S, 633 Gray AL, 1020 Botha JH, 1020 Flannery BE, 151 Greene DS, 974 Bourge RC, 673 Dal-Ré R, 420 Fliickiger SS, 681 Griffiths L, 688 Boxenbaum H, 763, 957 Darke AC, 37, 666 Follin SL, 351 Groenewoud G, 306 Branebjerg PE, 606 Davis CM, 128 Foote EF, 384 Grover J, 673 Brass EP, 189 Davis PJ, 52 Forbes KK, 505 Guerciolini R, 521, 856 Guillen GJ, 885 Kahn J, 856 Lin ET, 1094 Natarajan C, 688, 785 Guinta D, 259 Kaihlanen PM, 233 Lin S-K, 128 Nayak RK, 137, 379 Gupta SK, 159, 202, 493, Kaiko RF, 499 Links TP, 291 Nedelman J, 865 967, 985, 1083 Kakinoki S, 510 Lison AE, 1136 Nelluri SN, 588 Guzzo C, 865 Kallay Z, 681, 1136 Liu CY, 1094 Neuman Y, 599 Giiell A, 697 Karara AH, 865 Ljutic D, 1150 Nix DE, 196 Gyermek L, 845 Karim A, 384 Lloyd T, 202 Nomura A, 510 Karol MD, 815 Lo M-W, 1200 Norholt SE, 606 Hagen N, 37 Kaul S, 830 Longstreth J, 1083 Nozaki S, 478 Hahne WF, 705 Kazierad DJ, 151, 196, 807 Louie J, 259 Haidar S, 1174 Keane WF, 384, 622 Lowe N, 865 O’Connell MB, 18S Halabi A, 107 Kearns GL, 343, 739 Lowenthal DT, 885 Odink J, 821 Hall ST, 1174 Keefe DL, 1119 Lucki I, 410 O’Donnell D, 142 Halstenson CE, 137, 379, Keilani T, 87 Luke DR, 281 Ohashi K, 1067 384, 622 Keith M, 767 Ohmori K, 478 Hamel L, 259 Kemp SF, 739 Machinist JM, 815 Okerholm RA, 493 Hammett JL, 145 Kezer EA, 398 Mahachai V, 1071 Okin S, 541 Han R, 362 Kim YS, 22 Mak M, 856 Olivieri NF, 295 Harada K, 776, 1067 King JD, 529 Mammen E, 1194 Olsen KM, 739 Harris AG, 59 King S-YP, 1181 Mandal AK, 588 Onelli E, 285 Harsanyi Z, 37, 666 Kirch W, 107 Manning J, 145 Opsahl JA, 137, 379 Headlee D, 368 Kirdeikis P, 1071 Marathe PH, 974, 1109 Ordelova A, 351 Heimark L, 151 Kirshner M, 876 Marriage B, 1071 Osborne B, 1008 Hernandez RM, 426 Kishino S, 510 Martz R, 22 Ozawa T, 1194 Hinderling PH, 721 Kitabatake A, 510 Masotti G, 176 Hinrichsen H, 107 Klassen GA, 1144 Matsui D, 295 Padhi ID, 902 Hintze TH, 688 Klockowski PM, 410 Matsuo H, 478 Pan HY, 142 Hirabayashi K, 478 Kodama H, 995 Matzke GR, 137, 379 Panton LB, 885 Hochhaus G, 302, 1187 Kodama Y, 995 Mayol RF, 974 Parker BM, 673 Hoelscher DD, 73 Kokoris SP, 59 McCrea JB, 1200 Parker VD, 404, 410 Holloway S, 1194 Kombo I, 1025 McMahon FG, 484, 1060 Passe SM, 840 Hoover ME, 362 Kong A-NT, 1008 McNally C, 45 Pasutto FM, 1076 Houin G, 697 Koren G, 295 Mediratta S, 943 Patat A, 633 Hourani J, 800 Kornhauser DM, 1181 Mehta AV, 1016 Patel IH, 521, 1103 Hsieh JY-K, 1200 Kosoglou T, 151 Melia AT, 521, 840, 1103 Patel SB, 1025 Hsu H, 1060 Koss-Twardy SG, 281, 521, Meligeni J, 865 Patrick JE, 151 Hsu RS, 688 840 Metz A, 202 Pavy-Le Traon A, 697 Hu OY-P, 250 Kovarik JM, 1136 Meyer A, 681 Pedraz JL, 426 Hubbard JW, 688, 713 Krepostman A, 902 Middle MV, 306 Peirgies AA, 410 Huberfeld S, 541 Krumerman J, 885 Milbrath RL, 730 Peraudeau P, 471 Hui KK, 785 Kulkarni RD, 1025 Milla G, 521 Perel JM, 202 Hulse JD, 464 Kumagai Y, 1067 Millefiorini E, 627 Peter K, 856 Hundt HKL, 306 Kumar A, 541 Miller K, 529 Petit J-Y, 298 Hung OR, 1144 Kunka RL, 202 Miller R, 1020 Phelps SJ, 268 Hunt TL, 705 Kupiec JW, 1060 Min B, 521 Pieniaszek HJ, 1181 Hurley Dj, 800 Kuranari M, 995 Min BH, 840 Pieniaszek HJ Jr, 22 Hussey EK, 1174 Kurto HA, 1046 Minn FL, 379 Pieper JA, 268 Hwang SS, 159, 259, 985 Kutz K, 681 Miyazaki K, 510 Piepho RW, 443 Molinier P, 633 Piraino AJ, 390 Imbimbo BP, 285 La Cava G, 176 Moore M, 865 Piscitelli SC, 368 Ingenito AJ, 117 Lam YWF, 128 Morgan JM, 390 Pittman KA, 974 Iseki K, 510 Landau A, 747 Morganroth J, 163 Poggesi L, 176 Lantz MV, 967 Morino S, 627 Pollak PT, 1144 Jain AK, 45, 484 Lasheras L, 420 Morita H, 478 Pollock BG, 876 Jallad NS, 45 Lasseter KC, 145 Morris DM, 1174 Pollock ML, 885 Jamali F, 1071 Lathers CM, 333, 573, 1120 Mosca A, 285 Posvar EL, 990 James LP, 343 LeClair IO, 1016 Mollmann H, 302, 1187 Pouchus YF, 298 Jann MW, 128 Lee A, 1052 Mroczek WJ, 182 Pozuelo M, 895 Jauregui L, 529 Lee DR, 384 Mueller EA, 1136 Pritchard JF, 137 Jessup M, 673 Lee JS, 432, 1109 Muriel C, 426 Prueksaritanont T, 967 Jin J, 865 Lee JW, 464 Miller OF, 306 Pruvost P, 471 Johnson BF, 484 Levine JH, 52 Mycinsky C, 471 Johnston A, 681 Lewanczuk RZ, 1076 Mydlow PK, 1174 Radulovic LL, 990 Joly R, 1103 Licini M, 285 Myers CE, 368 Radwanski E, 151 Jorquera F, 895 Lieberman R, 368 Raines DA, 17, 615 Joshi AS, 1181 Lima JJ, 268 Nademanee K, 780 Rajagopalan R, 526 Joshi JC, 390 Lin CC, 1200 Naggar C, 673 Ram CVS, 1060 1210 Raymond R, 145 Schentag JJ, 151, 196 Sullivan TJ, 529 Wahab FA, 615 Raymond RH, 730, 1109 Schettino M, 285 Sun JX, 390 Waldman SA, 163, 1008 Redalieu E, 390 Schlueter W, 87 Sunaga K-I, 776 Wang Y-H, 541 Reddy K, 1052 Schmidt C, 681 Svensson CK, 902 Ward JL, 268 Reder RF, 499 Schnaper HW, 45 Sweet RA, 876 Wardle TS, 800 Reece PA, 526 Schraeder PL, 573, 1120 Simunic M, 1150 Ware JA, 902 Reed MD, 658 Schwartz J, 314, 529 Webb CR, 351, 902 Reese JH, 529 Schwartz JI, 362 Wei G, 493 Reitsma WD, 291 Sciagra R, 176 Takeyama M, 995 Weidler D, 45 Renner E, 1136 Scott M, 529 Tallarico D, 627 Weidler DJ, 673 Rice PJ, 1016 Sedman AJ, 526, 622, 990 Tam YK, 275 Weinberg J, 1052 Ripa S, 780 Seiberling M, 721 Tang H-S, 250 Weir MR, 73, 182, 220 Ritter W, 306 Shah A, 705 Tavenier P, 594 Weiss R, 780 Robertson S, 275 Shareef B, 541 Tavernini M, 1071 Welage LS, 374 Robinson D, 974 Shea MJ, 374 Taylor AM II, 807 Welin L, 298 Rock WL Jr, 526 Shukla UA, 830, 974 Taylor JR, 526 Wertheimer J, 673 Rohatagi S, 302, 1187 Shyu WC, 432 Teller SB, 281 Whelton A, 233, 454 Rolf CN, 493, 985 Sieck JO, 615 Tendolkar A, 721 Whipple JP, 673 Roncari G, 821 Simon JS, 182 Teplitzky Y, 599 White RM, 1156 Rongen GA, 357 Simpson I, 1071 Thibault A, 368 White WB, 233 Rose S, 374 Simpson K, 865 Thien T, 357 Whitfield LR, 990 Rosemurgy AS II, 1046 Sindet-Pedersen S, 606 Thirlwell MP, 37 Williams L, 885 Rowe HM, 170 Singh S, 780 Thomson ABR, 1071 Wilson JM, 398 Rubins HB, 767 Skerjanec A, 275 Tisdale JE, 351, 902 Wilson MF, 807 Rudd P, 484 Skoularigis J, 1052 Toddywalla VS, 1025 Wilton JH, 807 Rudis MI, 902 Smit AJ, 291 Tomasko L, 362, 1008, 1200 Wittkowsky AK, 1031 Rudolph G, 202 Smith BL, 840 Tomlanovich SJ, 967 Wojcik GJ, 196 Rumboldt Z, 1150 Smith E, 673 Tompkins A, 368 Wong MO, 622 Smith ER, 398 Topmiller MJ, 52 Wooles WR, 117 Sackler RS, 499 Smith HT, 1136 Toth PD, 45 Wright B, 876 Sagraves R, 2S Smith RA, 785 Triscari J, 142 Wurzel M, 599 Sainati SM, 713 Smithurst B, 31 Troy S, 1194 Saivin S, 697 Smits P, 357 Troy SM, 404, 410 Xilinas M, 22 Salazar DE, 730, 1109 Sourgens H, 302, 1187 Tsutsumi K, 995 Sambol NC, 1094 Southam MA, 159 Tiirck D, 622 Yamashita TS, 658 Samid D, 368 Sowers JR, 484 Yeh KC, 362, 529 Sampson J, 31 Sowinski KM, 807 Uderman HD, 730, 1109 Yeung PFK, 1144 Sansegundo D, 895 Spachynski K, 666 Underwood B, 526 Yih BM, 1083 Sardelic S, 1150 Sramek JJ, 800 Underwood BA, 622 Yoshikawa K, 478 Sareli P, 1052 Srinivas NR, 432 Upmalis D, 432 Yu H-S, 128 Sasaki M, 776 Stauffer LA, 362 Yuen GJ, 1174 Satoh H, 281 Stepanavage M, 529 Satterwhite JH, 800 Stewart W, 705 van Brummelen P, 821 Zafrir N, 599 Saxena BN, 1025 Stimpel M, 233, 794 Van Harken DR, 145 Zarowitz BJ, 902 Saxton TD, 22 Stitzel V, 588 Vara F, 426 Zecca L, 285 Schafer AI, 209 Stokes A, 45 Venter CP, 244 Zell M, 821 Schall! R, 306 Stone WL, 1016 Ver Donck K, 357 Zhi J, 281, 521, 840, 1103 Schange SJ, 398 Strugo V, 1052 Verbist J-F, 298 Zinny M, 142 Scheck F, 471 Sugawara M, 510 Vivas C, 885 Zuk L, 1071 Subject Index, Volume 35 (1995) Acetaminophen Adverse Effects BRL 49653C pharmacokinetics and, A926 for muscle-contraction headache, A929 amiodarone noncardiovascular adverse effects, CGP 36742 pharmacokinetics and, A922 for orthodontic pain in children, A929 351 linopirdine in healthy young adults and elderly Acromegaly enalapril, 484 volunteers, 22 subcutaneous octreotide infusion for, 59 isradipine, 484 metformin pharmacokinetics and, 1094 Adolescents. See Pediatrics mitoxantrone, 627 sibutramine pharmacokinetics and, A928 Adrenaline tyramine during benfloxatone treatment, 633 Albumin interaction with lidocaine, 426 Age. See also Geriatrics; Pediatrics interferon alfa-2a bioequivalency, 281 Adrenocorticotropic Hormone aging effects on antipyrine clearance, 895 Aldosterone losartan effects on response of cortisol and aldo- atenolol pharmacokinetics and pharmacody- losartan effects on response to adrenocortico- sterone to, 776 namics and, 807 tropic hormone, 776 Alosetron Antithrombotic Therapy Butorphanol Tartrate Nasal Spray interaction with haloperidol, 202 heparin in, 1031 interaction with sumatriptan succinate, 432 Alpha-1-Acid Glycoprotein Anuria disopyramide protein binding and, 510 gabapentin disposition subjects on hemodialysis, Calcium Antagonists. See also specific agents Alprostadil 622 for congestive heart failure, 443 efficacy and safety in erectile dysfunction, A937 Ardeparin Cancer. See Oncology Altitude. See High Altitude pharmacokinetics, 1194 Carbamazepine Alzheimer’s Disease Area Under the Inhibitory Curve pharmacokinetics, 995 xanomeline tartrate safety and efficacy in, 800 as target for optimization of dosing regimens of Carbamazepine-10 American College of Clinical Pharmacology antibiotics, A926 pharmacokinetics, 995 symposium from 1993 annual meeting, 72 Arrhythmias Carbimazole Amiodarone atropine effects on parasympathetic control of re- interaction with digoxin, A922 noncardiovascular adverse effects, 351 spiratory sinus arrhythmia, 244 Carboplatin Amitriptyline cibenzoline versus flecainide in prevention of pharmacokinetics, 1003 enzyme kinetic modeling as tool in identifying paroxysmal atrial arrhythmias, 471 Cardiopulmonary Resuscitation metabolic pathways, A926 inability to tolerate long term drug therapy as in- regional blood flow measurement during, A935 pharmacokinetics, 17 dication for radiofrequency catheter ablation Cardiovascular System. See also Antihyperten- Amlodipine of supraventricular arrhythmias, A927 sive Agents; Arrhythmias; Hypertension amlodipine and benazepril monotherapy com- Aspirin amiodarone noncardiovascular adverse effects, pared with amlodipine plus benazepril in sys- pharmacodynamics, 1181 351 temic hypertension, 1060 pharmacokinetics, 1181 amlodipine and benazepril monotherapy com- Amrinone Asthma pared with amlodipine plus benazepril in sys- venodilatory effect compared with theophylline, computer-based system of instruction on new temic hypertension, 1060 1067 perspectives in prevention and treatment of, amlodipine effects in black patients with very se- Analgesics. See also Nonsteroidal anti-inflam- vere hypertension, 1052 matory drugs; specific analgesics Atenolol amrinone and theophylline venodilatory effects lornoxicam, 606 pharmacodynamics, 807 compared, 1067 morphine, 666 pharmacokinetics, 268, 807 anthracycline cardiotoxicity, A935 over-the-counter, renal effects of, 454 Atorvastatin antianginal and antiischemic efficacy of nisoldip- Anesthetics pharmacokinetics, 990 ine in chronic stable angina, 780 eutectic mixture of local anesthetics for pro- Atropine atropine effects on parasympathetic control of re- longed subcutaneous drug administration, 295 parasympathetic control of respiratory sinus ar- spiratory sinus arrhythmia, 244 Angina rhythmia and, 244 calcium antagonist therapy for congestive heart antianginal and antiischemic efficacy of nisoldip- failure, 443 ine in chronic stable angina, 780 cardiovascular actions and cardioprotective ben- dose-ranging study ofd iltiazem for stable angina, Benazepril efits of estrogen replacement therapy in post- 189 amlodipine and benazepril monotherapy com- menopausal women, 306 Angiotensin-Converting Enzyme Inhibitors. See pared with amlodipine plus benazepril in sys- cardiovascular pharmacokinetics of bespiridine also specific agents temic hypertension, 1060 hydrochloride, 688 for hypertension, 337 Benfloxatone cibenzoline versus flecainide in prevention of in renal disease, 87 adverse effects, 633 paroxysmal atrial arrhythmias, 471 Angiotensin-II Bepridil diltiazem dose-ranging study for stable angina, valsartan pressor response to, A930 pharmacokinetics, 137, 379 189 Anthracycline Bespiridine Hydrochloride diltiazem for hypertension, 220 cardiotoxicity of, A935 pharmacokinetics, 688 dolasetron dose-ranging safety evaluation, 713 Antibiotics. See also specific agents Bidisomide fosinopril pharmacodynamics in congestive area under the inhibitory curve as target for opti- food and absorption and disposition profiles of, heart failure, 785 mization of dosing regimens of, A926 A921 head-down tilt effects on lidocaine pharmacoki- Antidepressant Agents. See also specific agents food and plasma levels of, A921 netics as probe to evaluate hepatic blood flow, cyclic antidepressant toxicity in children and ad- Bioavailability. See Pharmacokinetics 697 olescents, 343 Bioequivalence H,-receptor antagonist effects, 107 Antiepileptic Agents. See also specific agents interferon alfa-2a and human serum albumin iloperidone pharmacokinetics, 713 clinical pharmacology of, 1120 content, 281 isradipine-CR for sustained blood pressure con- experience-based teaching of therapeutics and morphine using naltrexone blockade, 499 trol, 239 clinical pharmacology of, 573, A940 statistical difference in analysis of variance and, lisinopril for heart failure, 673 Antihypertensive Agents. See also Renal Func- A931 losartan effects on response of cortisol and aldo- tion; specific agents verapamil sustained-release formulations, 163 sterone to adrenocorticotropic hormone, 776 indapamide, 45 Bisoprolol lovastatin effects on early restenosis, 599 verapamil, 52 low-dose, with low-dose hydrochlorothiazide for low-dose bisoprolol and low-dose hydrochloro- Antiinflammatory Agents. See also specific hypertension, 182 thiazide therapy, 182 agents Blood Flow mexiletine effects on left ventricular contractil- cordiachromene A, 298 regional blood flow measurement during cardio- ity in congestive heart failure, 478 platelet function and systemic hemostasis and, pulmonary resuscitation, A935 mitoxantrone cardiotoxicity in relapsing remit- 209 Blood Pressure. See also Antihypertensive ting multiple sclerosis, 627 triamcinolone acetonide pharmacokinetics, 302, Agents; Hypertension moexipril efficacy assessment, 233 1187 gender differences in exercise and recovery moexipril versus verapamil for mild to moderate triamcinolone acetonide pharmacodynamics, blood pressures in normal volunteers given dil- hypertension, 794 1187 tiazem, 1144 phentolamine antagonism of norepinephrine-in- Antimicrobial Agents. See also Antibiotics; spe- Body Position duced hand vein constriction, 170 cific agents norverapamil pharmacokinetics and pharmaco- phenytoin effects on plasma high-density lipo- quantitative evaluation of activity on the hand dynamics, 1083 protein cholesterol levels in men with low lev- using intrapersonal flora translocation, A932 verapamil pharmacokinetics and pharmacody- els of high-density lipoprotein cholesterol, 767 Antipsychotic Agents. See also specific agents namics, 1083 renal and limb vasodilation during acute beta- iloperidone, 713 Breast-Feeding adrenoreceptor blockade with indenolol, 176 Antipyretic Agents alteration of nursing infant's hepatic drug metab- serotonin and serotonin antagonism in cardio- ibuprofen, A929 olizing pattern by chronic maternal therapy, vascular and noncardiovascular disease, 541 naproxen, A929 1025 Cefoperazone Antipyrine BRL 49653C pharmacokinetics, 250 aging effects on clearance, 895 pharmacokinetics, A926 Ceftizoxime antipyrine metabolism and acetylation pheno- Bupropion pharmacokinetics, 1046 type in health and chronic liver diseases, 615 pharmacokinetics, 876 in trauma celiotomy, 1046 1212 Celiotomy immunopharmacodynamic studies in patients diprafenone hydrochloride and propranolol hy- ceftizoxime in trauma celiotomy, 1046 awaiting renal transplantation, 967 drochloride, 721 Central Nervous System. See also Antipsychotic pharmacokinetics, 681 famotidine and theophylline, 529 Agents Cytochrome P450 Enzymes 5-fluorouracil and methotrexate, 1156 alosetron effects on haloperidol pharmacokinet- inhibition by monoclonal and polyclonal anti- fosinopril and hydrochlorothiazide, A924 ics in schizophrenia, 202 bodies, A925 gentamicin and verapamil, 196 mitoxantrone cardiotoxicity in relapsing remit- venlafaxine metabolism and, A936 glyburide and orlistat, 521 ting multiple sclerosis, 627 Cytokines haloperidol and alosetron, 202 xanomeline tartrate safety and efficacy in Alz- ciprofloxacin and, A924 hydrochlorothiazide and fosinopril, A924 heimer’s disease, 800 Cytotoxic Drugs hydrochlorothiazide and losartan, 1200 CGP 36 742 tamoxifen with for non-Hodgkin's lymphoma, lidocaine and adrenaline, 426 pharmacokinetics, A922 A936 losartan and hydrochlorothiazide, 1200 Children. See Pediatrics losartan and warfarin, 1008 Chlorthalidone methotrexate and 5-fluorouracil, 1156 interaction with ramipril, 1150 Death N-acetylprocainamide and para-aminobenzoic ramipril decrease of loss of magnesium and po- sudden unexplained death in epilepsy, 573, A940 acid, 902 tassium in hypertension induced by, 1150 Depression. See also Antidepressant Agents; spe- nefazodone and dextromethorphan, A925 Cholesterol cific agents nefazodone and propranolol, 1109 ibuprofen cholesterol isomers and, A939 bupropion pharmacokinetics in elderly patients nefazodone and warfarin, 730 phenytoin effects on plasma high-density lipo- with, 876 orlistat and digoxin, 840 protein cholesterol levels in men with low lev- Dermatology orlistat and glyburide, 521 els of high-density lipoprotein cholesterol, 767 nonsteroidal anti-inflammatory drugs in, A932 para-aminobenzoic acid and N-acetylprocai- terazosin effects in patients with diabetes melli- Dextromethorphan namide, 902 tus and hypertension and, A934 interaction with nefazodone, A925 para-aminobenzoic acid and procainamide, 902 Chronic Disease Dezocine procainamide and para-aminobenzoic acid, 902 clinical trials in, 594 pharmacokinetics, 398 propranolol and nefazodone, 1109 Chronic Obstructive Pulmonary Disease Diabetes Mellitus propranolol hydrochloride and diprafenone hy- famotidine and theophylline interaction in, 529 antihypertensive therapy in, 73 drochloride, 721 Cibenzoline glyburide protein binding and effect of albumin ramipril and chlorthalidone, 1150 in prevention of paroxysmal atrial arrhythmias, glycation in, 739 rivastatin and warfarin, 306 471 terazosin effects on glycemic control, cholesterol, sparfloxacin and theophylline, A936 Ciprofloxacin and microalbuminuria in patients with diabe- sumatriptan succinate and butorphanol tartrate cytokine production and tacrolimus and, A924 tes mellitus and hypertension and, A934 nasal spray, 432 Cirrhosis Diazepam tacrine and warfarin, 526 galactose single point method as measure of re- interaction with venlafaxine, 410 tetanus-diphtheria vaccine and tetanus immune sidual liver function, 250 Digoxin globulin, 420 Citrus Fruits interaction with carbimazole, A922 tetanus immune globulin and tetanus-diphtheria tandem mass spectrometry for in vivo flavanone interaction with orlistat, 840 vaccine, 420 evaluation and, A923 Dihematoporphyrin theophylline and famotidine, 529 Clavulanic Acid pharmacokinetics, A936 theophylline and sparfloxacin, A936 ticarcillin/clavulanic acid dese recommenda- Diltiazem venlafaxine and diazepam, 410 tions for infants and children, 658 clinical experience in hypertension, 220 verapamil and gentamicin, 196 Clinical Pharmacology diltiazem ER for severe hypertension, A923 warfarin and losartan, 1008 effective half-life in, 763 dose-ranging study of diltiazem for stable angina, warfarin and nefazodone, 730 experience-based teaching of therapeutics and 189 warfarin and rivastatin, 306 clinical pharmacology of antiepileptic drugs, gender differences in exercise and recovery warfarin and tacrine, 526 573, A940 blood pressures in normal volunteers given dil- DuP 996. See Linopirdine surrogate biochemical markers and, 441 tiazem, 1144 DuP 753/MK 954. See Losartan teaching clinical pharmacology of antiepileptic pharmacokinetics, A924 drugs, 1120, A940 Diprafenone hydrochloride teaching pharmacology in the informatics age, interaction with propranolol hydrochloride, 721 Editorial Disopyramide presidential address, 333 A940 food and absorption and disposition profiles of, The Tradition of Scientific Publication, 1119 training utilizing telecommunication technol- ogy, A934 A921 Education protein binding, 510 Clinical Pharmacology Problem Solving (CPPS) Clinical Pharmacology Problem Solving Unit DMP 450 Unit, 1120 CPPS unit on antiepileptic drugs, 1120 pharmacokinetics, A933 clinical therapeutic approach for teaching health Clinical Trials DMP 504 care professionals about drug-induced disease, in chronic diseases, 594 safety and tolerance, A934 A940 Congestive Heart Failure Dolasetron computer-based system of instruction on new calcium antagonist therapy for, 443 dose-ranging safety evaluation of, 713 perspectives in prevention and treatment of fosinopril pharmacodynamics in, 785 Drug Development asthma, A933 mexiletine effects on left ventricular contractil- bidisomide, A921 experience-based teaching of therapeutics and ity in, 478 concentration-guided strategies, 1136 clinical pharmacology of antiepileptic drugs, Cordiachromene A disopyramide, A921 573, A940 antiinflammatory mechanism, 298 surrogate biochemical markers, 464 student feedback comments on examinations, Cortisol Drug-Induced Disease A940 clinical therapeutic approach for teaching health survey results of POPS use, 117 losartan effects on response to adrenocortico- care professionals about, A940 teaching clinical pharmacology of antiepileptic tropic hormone, 776 Drug Interactions drugs, A940, 1120 suppression after oral administration of fluocor- adrenaline and lidocaine, 426 teaching pharmacology in the informatics age, tolone, A926 Critical Care abluotsoertprhoan noaln d thaartlroapteer idnoals,a l 20s2p ray and sumatrip- traAi9n4i0ng utilizing telecommunication technol- high-grade nucleoside transport inhibition stim- tan succinate, 432 ogy, A934 Crouhlant’isn g Divsenetaislea tion, 357 carbimazole and digoxin, A922 EElldeecrtlryo cPaartdieinotgsr.a pSheye Geriatrics cyclosporine pharmacokinetics in, 681 chlorthalidone and ramipril, 1150 amlodipine effects in black patients with very se- Cyclosporine dextromethorphan and nefazodone, A925 vere hypertension, 1052 concentration-guided strategies in development diazepam and venlafaxine, 410 Electroencephalography for transplantation, 1136 digoxin and carbimazole, A922 psychological performance parameters under cyclosporine A pharmacokinetics, 865 digoxin and orlistat, 840 scopolamine correlated with, A922 1213 EMLA Cream Food Heart. See Left Ventricular Function efficacy for venipuncture, A924 avortavastatin bioavailability and, 990 Heart Failure. See also Congestive heart failure Enalapril bidisomide absorption and disposition profiles, lisinopril for, 673 adverse effects, 484 A921 Helicobacter Pylori for severe hypertension, A923 bidisomide plasma level, A921 gastrointestinal disease and, 647 Endocrinology disopyramide absorption and disposition profiles, impaired gastric electrical rhythm in Helico- losartan effects on response of cortisol and aldo- A921 bacter pylori infected subjects, A921 sterone to adrenocorticotropic hormone, 776 iloperidone pharmacokinetics and, 713 Hemodialysis pinacidil effects on insulin release, 291 isosorbide-5-mononitrate bioavailability and, bepridil plasma protein binding and, 137 subcutaneous octreotide infusion for acromeg- 151 carboplatin pharmacokinetics in cervical cancer aly, 59 norverapamil pharmacokinetics and pharmaco- with ureteric obstruction before, during, and Enzymes dynamics, 1083 after, 1003 enzyme kinetic modeling as tool in identifying reduced dietary fat absorption induced by orlis- gabapentin disposition in anuric subjects on, 622 metabolic pathways, A926 tat and digoxin pharmacokinetics, 840 lansoprazole pharmacokinetics and, 815 Epidemiology. See Pharmacoepidemiology retinoid pharmacokinetics and, A930 Hemostasis Epilepsy. See also Antiepileptic Agents; specific sibutramine metabolite bioavailability and, A927 nonsteroidal anti-inflammatory drug effects on, agents verapamil bioequivalence and, 163 carbamazepine and carbamazepine-10 bound se- verapamil pharmacokinetics and pharmacody- Heparin rum concentration prediction after polyther- namics and, 1083 in antithrombotic therapy, 1031 apy in, 995 Fosinopril ardeparin pharmacokinetics, 1194 sudden unexplained death in, 573, A940 interaction with hydrochlorothiazide, A924 Hepatic Function Eptastigmine pharmacodynamics, 785 alteration of nursing infant’s hepatic drug metab- pharmacodynamics, 285 pharmacokinetics, 145 olizing pattern by chronic maternal therapy, pharmacokinetics, 285 Fosinoprilat 1025 Erectile Dysfunction pharmacokinetics, 145 antipyrine metabolism and acetylation pheno- alprostadil safety and efficacy in, A937 type in health and chronic liver diseases, 615 Estrogens Gabapentin fosinopril and fosinoprilat in hepatic impair- benefit/risk of estrogen therapy in cardiovascu- pharmacokinetics, 622 ment, 145 lar disease, 11S Gastrointestinal System galactose single point method as measure of re- cardiovascular actions and cardioprotective ben- cyclosporine pharmacokinetics in Crohn’s Dis- sidual liver function, 250 efits of replacement therapy in postmeno- ease, 681 head-down tilt effects on lidocaine pharmacoki- pausal women, 314 Helicobacter pylori and gastrointestinal disease, netics as probe to evaluate hepatic blood flow, estarnodg epnr etvheenrtaipoyn foofr osptoesotpmoreonsoipsa,u s2aSl symptoms imp6a47i red gastric electrical rhythm in Helico- tra6n9d7o lapril pharmacokinetics in fatty liver dis- future therapeutic developments, 25S bacter pylori infected subjects, A921 ease, A922 . pharmacokinetic and pharmacologic variation methyldopa presystemic gut metabolism, 275 verapamil pharmacokinetics in fatty liver dis- between estrogen products, 18S oral medication delivery system for famotidine, ease, A922 Exercise High Altitude gender differences in exercise and recovery pra3v6a2s tatin absorption in healthy subjects, 142 meperidine and normeperidine excretion upon blood pressures in normal volunteers given dil- Gender exposure to, A931 tiazem, 1144 gender differences in exercise and recovery meperidine pharmacokinetics upon exposure to, propranolol pharmacokinetics in young and el- blood pressures in normal volunteers given dil- A931 derly adults and, 885 tiazem, 1144 HIV. See Human Immunodeficiency Virus EXP3174 Genetics. See Pharmacogenetics HP 749. See Bespiridine Hydrochloride plasma protein binding, 515 Gentamicin HP 873. See Iloperidone interaction with verapamil, 196 H,-Receptor Antagonists Famotidine Geriatrics cardiovascular effects, 107 interaction with theophylline, 529 bupropion pharmacokinetics in elderly patients 5-HT, Receptors oral medication delivery system for, 362 with depression, 876 pharmacologic and therapeutic aspects of, 845 Fatty Liver Disease CGP 36 742 pharmacokinetics and, A922 Human Immunodeficiency Virus trandolapril pharmacokinetics in, A922 flucloxacillin in elderly hospitalized patients, 31 pentamidine pharmacokinetics in prophylaxis of verapamil pharmacokinetics in, A922 indapamide for hypertension in elderly patients, Pneumocystis carinii pneumonia in patients Felodipine infected with, 1166 pharmacokinetics, A938 lac4k5 of effect of aerobic exercise on propranolol Hydrochlorothiazide vasodilating properties, A938 pharmacokinetics in young and elderly adults interaction with fosinopril, A924 Fenoldopam interaction with losartan, 1200 pphhaarrmmaaccookdiynnetaimcisc,s , A9A3923 2 linavonopdli,ur ndt8ie8ne5er s,i n 2h2e althy young adults and elderly lows-iodno,s e1,8 2w ith low-dose bisoprolol for hyperten- Fentanyl pharmacokinetics, 1200 pharmacokinetics, 159 sibtiuetnrtas,m iAn9e2 8p harmacokinetics and in elderly pa- Hydromorphone FtFllaeanofcvd,aae iAnmn9o i2ndm3eea s s s spectrometry for in vivo evaluation Ggiln!tyygebblruyuarcrciaitdtdieioeo n n p rwiointt edhii nao brelbtiiesntsda,ti ,n 7g35 92 1a nd effect of albumin pHpHhhyyaapdrrermmroaatmcceooonkrksiipinnoheenott.nii ecc-ss,3,S -eG33el77 ucualrsoon ideA ntihypertensive in prevention of paroxysmal atrial arrhythmias, Agents; specific agents Granulocyte-Macrophage Colony Stimulating 471 Factor amlodipine and benazepril monotherapy com- Fplhuacrlmoaxcaockiilnleitni cs, 31 zidovudine pharmacokinetics and, 856 ptaemriecd hwyipthe rtaemnlsoidoinp,i n1e0 60p lus benazepril in sys- Fluocortolone amlodipine effects in black patients with very se- pharmacodynamics, A926 Haloperidol vere hypertension, 1052 pharmacokinetics, A926 interaction with alosetron, 202 angiotensin-converting enzyme inhibitor ther- 5-Fluorouracil intra- and interethnic variability in reduced hal- apy for, 337 interaction with methotrexate, 1156 operidol to haloperidol ratios, 128 diltiazem for, 220 Fluoxetine pharmacokinetics, 202 enalapril and diltiazem ER compared in severe enantiomers of, A938 risperidone compared with for schizophrenia, hypertension, A923 pharmacokinetics, 17 A937 fenoldopam pharmacodynamics in moderately Flurbiprofen Headaches severe hypertension, A932 pharmacodynamics, A925 ibuprofen and acetaminophen for muscle-con- indapamide therapy in elderly patients with, 45 pharmacokinetics, A925 traction headache, A929 insulin resistance in systemic hypertension, 943 Fluticasone Heart. See Arrhythmias; Cardiovascular Sys- isradipine and enalapril adverse effects com- input rate into systemic circulation, A927 tem; Congestive heart failure pared, 484 1214 isradipine-CR for sustained blood pressure con- Leg Cramps Moexipril trol, 239 quinine for, 588 efficacy assessment, 233 management of hypertensive urgencies and Leukotriene B, verapamil versus, for mild to moderate hyperten- emergencies, 747 inhibition in healthy males, A930 sion, 794 moexipril versus verapamil for mild to moderate Lidocaine Monoclonal Antibodies hypertension, 794 head-down tilt effects on lidocaine pharmacoki- cytochrome P450 enzyme inhibition by, A925 ramipril decrease of chlorthalidone-induced loss netics as probe to evaluate hepatic blood flow, Moricizine of magnesium and potassium in, 1150 697 pharmacokinetics, 1016 terazosin effects on glycemic control, cholesterol, interaction with adrenaline, 426 Morphine and microalbuminuria in patients with diabe- pharmacokinetics, 426 in cancer pain, 666 tes mellitus and hypertension and, A934 Linopirdine effect on postoperative pain following total ab- Hypogonadism pharmacokinetics, 17 dominal hysterectomy or myomectomy, A927 testosterone pharmacokinetics in, A923 Lipids. See also Orlistat pharmacokinetics, 499 ACE therapy in renal disease and, 87 Multiple Sclerosis Ibuprofen phenytoin effects on plasma high-density lipo- mitoxantrone cardiotoxicity in relapsing remit- antipyretic efficacy in upper respiratory illness, protein cholesterol levels in men with low lev- ting multiple sclerosis, 627 A929 els of high-density lipoprotein cholesterol, 767 cholesterol isomers and, A939 reduced dietary fat absorption induced by orlis- N-Acetylprocainamide disposition of stereoisomers in presence of non- tat and digoxin pharmacokinetics, 840 interaction with para-aminobenzoic acid, 902 linear plasma protein binding, A939 5-Lipogenase Inhibitor 6-8-Naltrexol efficacy with pseudoephedrine for nasal conges- leukotriene B, inhibition and, A930 pharmacokinetics, A933 tion, A929 Lisinopril Naltrexone for muscle-contraction headache, A929 for heart failure, 673 morphine bioequivalence, 499 for orthodontic pain in children, A929 Liver. See Hepatic Function pharmacokinetics, A933 pharmacodynamics, A925 Lornoxicam Naproxen pharmacokinetics, A925 analgesic effect after surgical removal of mandib- antipyretic efficacy in upper respiratory illness, tolerance and efficacy of, A938 ular third molars, 606 A929 lloperidone Losartan Nasal Congestion pharmacokinetics, 713 effects on response of cortisol and aldosterone to ibuprofen efficacy with pseudoephedrine for na- Immunology adrenocorticotropic hormone, 776 sal congestion, A929 immunopharmacodynamic studies of cyclospor- interaction with hydrochlorothiazide, 1200 Nefazodone ine in patients awaiting renal transplantation, interaction with warfarin, 1008 interaction with dextromethorphan, A925 967 pharmacokinetics, 1200 interaction with propranolol, 1109 Indapamide plasma protein binding, 515 interaction with warfarin, 730 for mild to moderate hypertension in elderly pa- Lovastatin pharmacodynamics, 1109 tients, 45 early restenosis and, 599 pharmacokinetics, 830, 974, 1109 Indenolol Nicotine renal and limb vasodilation during acute beta- Magnesium pharmacokinetics, 493, 985 adrenoreceptor blockade with, 176 ramipril decrease of chlorthalidone-induced loss Nisoldipine Infants. See Pediatrics in hypertension, 1150 antianginal and antiischemic efficacy in chronic Infectious Diseases Marfan Syndrome stable angina, 780 ceftizoxime in trauma celiotomy, 1046 atenolol absorption pharmacokinetics in, 268 Nitroglycerin pentamidine pharmacokinetics in prophylaxis of Mass Spectrometry pharmacokinetics, 390 Pneumocystis carinii pneumonia in patients dual selective detection of stable isotope labeled Nizatidine infected with human immunodeficiency virus, drug in whole urine using, A935 pharmacokinetics, 1071 1166 selective detection of stable isotope labeled drug Nonsteroidal Anti-Inflammatory Drugs. See also Insulin in serum using, A935 specific agents insulin resistance in systemic hypertension, 943 tandem mass spectrometry for in vivo flavanone in dermatology, A932 pinacidil effects on release of, 291 evaluation and, A923 platelet function and systemic hemostasis and, Interferon Alfa-2a Medical Delivery Systems 209 pharmacokinetics, 281 oral medication delivery system for famotidine, Norepinephrine Ischemia 362 phentolamine antagonism of hand vein constric- antianginal and antiischemic efficacy of nisoldip- Menopause. See Estrogens tion induced by, 170 ine in chronic stable angina, 780 Meperidine Normeperidine Isosorbide-5-Mononitrate pharmacokinetics, A931 urinary excretion of, A931 pharmacokinetics, 151 for sickle cell painful episodes, A937 Norverapamil Isotretinoin urinary excretion of, A931 pharmacodynamics, 1083 systemic absorption of isotretinoin cream, A930 Metabolism pharmacokinetics, 1076, 1083 Isradipine enzyme kinetic modeling as tool in identifying Nucleosides adverse effects, 484 metabolic pathways, A926 high-grade nucleoside transport inhibition stim- Isradipine-CR venlafaxine, A936 ulating ventilation, 357 sustained blood pressure control, 239 Metformin pharmacokinetics, 1094 Methodology Ketorolac clinical trials in chronic diseases, 594 Obesity ketorolac adenylate in chiral inversion of, A939 galactose single point method as measure of re- sibutramine pharmacokinetics and, A928 for sickle cell painful episodes, A937 sidual liver function, 250 Octreotide Kidney. See Renal Disease; Renal Function Methotrexate for acromegaly, 59 interaction with 5-fluorouracil, 1156 Oncology Lactation Methyldopa adrenalin and lidocaine interaction in pancreatic alteration of nursing infant’s hepatic drug metab- pharmacokinetics, 275 neoplasia, 426 olizing pattern by chronic maternal therapy, Mexiletine carboplatin pharmacokinetics in cervical cancer 1025 left ventricular contractility in congestive heart with ureteric obstruction before, during, and Lamivudine failure and, 478 after hemodialysis, 1003 pharmacokinetics, 1174 Microalbuminuria hydromorphone and hydromorphone-3-glucuro- Lansoprazole terazosin effects in patients with diabetes melli- nide and, 37 pharmacokinetics, 815 tus and hypertension and, A934 methotrexate modulation by 5-fluorouracil, 1156 Left Ventricular Function Misoprostol morphine for cancer pain, 666 amlodipine effects in black patients with very se- pharmacokinetics, 384 phenylbutyrate, phenylacetate, and phenylacet- vere hypertension, 1052 Mitoxantrone ylglutamine disposition, 368 mexiletine effects on left ventricular contractil- cardiotoxicity in relapsing remitting multiple tamoxifen with cytotoxic drugs for non-Hodg- ity in congestive heart failure, 478 sclerosis, 627 kin’s lymphoma, A936 Organ Transplantation bupropion, 876 Phenylacetylglutamine concentration-guided strategies in development carbamazepine, 995 disposition, 368 for transplantation, 1136 carbamazepine-10, 995 Phenylbutyrate immunopharmacodynamic studies of cyclospor- carboplatin, 1003 disposition, 368 ine in patients awaiting renal transplantation, cefoperazone, 250 Phenytoin 967 ceftizoxime, 1046 effects on plasma high-density lipoprotein cho- Orlistat CGP 36 742, A922 lesterol levels in men with low levels of high- interaction with digoxin, 840 cyclosporine, 681 density lipoprotein cholesterol, 767 interaction with glyburide, 521 cyclosporine A, 865 pharmacokinetics, A928 pharmacokinetics, 1103 dezocine, 398 Pinacidil Osteoporosis dihematoporphyrin, A936 insulin release in healthy volunteers and, 291 estrogen therapy for prevention of, 2S diltiazem, A924 Piroxicam Oxprenolol DMP 450, A933 intradermal toxicity of, A934 pharmacokinetics, A939 effective half-life in clinical pharmacology, 763 P-450 Isoforms eptastigmine, 285 cocktail strategy for, 655 estrogens, 18S Platelet Function Pain. See also Analgesics; specific agents felodipine, A938 nonsteroidal anti-inflammatory drug effects on, dezocine pharmacokinetics and, 398 fenoldopam, A932 209 ibuprofen and acetaminophen for orthodontic fentanyl, 159 Pneumocystis Carinii Pneumonia pain in children, A929 first-time-in-human dose selection, 957 pentamidine pharmacokinetics in prophylaxis morphine effect on postoperative pain following flucloxacillin, 31 of, 1166 total abdominal hysterectomy or myomec- fluocortolone, A926 Polyclonal Antibodies tomy, A927 fluoxetine, 17 cytochrome P450 enzyme inhibition by, A925 Para-aminobenzoic acid flurbiprofen, A925 POPS. See Patient-Oriented Problem-Solving interaction with N-acetylprocainamide, 902 fosinopril, 145 Potassium interaction with procainamide, 902 fosinoprilat, 145 ACE therapy in renal disease and, 87 Patient-Oriented Problem-Solving gabapentin, 622 ramipril decrease of chlorthalidone-induced loss survey results of use, 117 haloperidol, 202 in hypertension, 1150 Pediatrics hydrochlorothiazide, 1200 Pravastatin alteration of nursing infant’s hepatic drug metab- hydromorphone, 37 pharmacokinetics, 142 olizing pattern by chronic maternal therapy, hydromorphone-3-glucuronide, 37 Predictive Testing 1025 ibuprofen, A925 role ofi n vivo and in vitro testing, A931 cyclic antidepressant toxicity, 343 iloperidone, 713 Procainamide eutectic mixture of local anesthetics for pro- interferon alfa-2a, 281 interaction with para-aminobenzoic acid, 902 longed subcutaneous drug administration, 295 isosorbide-5-mononitrate, 151 Propranolol glyburide protein binding and effect of albumin lamivudine, 1174 interaction with diprafenone hydrochloride, 721 glycation in diabetes, 739 lansoprazole, 815 interaction with nefazodone, 1109 ibuprofen and acetaminophen for orthodontic lidocaine, 426 pharmacodynamics, 1109 pain, A929 linopirdine, 22 pharmacokinetics, 374, 885, 1109 moricizine pharmacokinetics, 1016 losartan, 1200 Protein Binding ticarcillin/clavulanic acid dose recommenda- meperidine, A931 bepridil, 137 tions for infants and children, 658 metformin, 1094 carbamazepine and carbamazepine-10 bound se- valproate clearance value estimation in children, methyldopa, 275 rum concentration prediction after polyther- 1020 misoprostol, 384 apy in epilepsy, 995 Pentamidine moricizine, 1016 disopyramide, 510 pharmacokinetics, 1166 morphine, 499 EXP3174, 515 Peptic Ulcer Disease 6-6-naltrexol, A933 glyburide protein binding and effect of albumin nizatidine pharmacokinetics in, 1071 naltrexone, A933 glycation in diabetes, 739 Pharmacodynamics nefazodone, 830, 974, 1109 ibuprofen stereoisomers distribution in presence aspirin, 1181 nicotine, 985 of nonlinear plasma protein binding, A939 atenolol, 807 nicotine transdermal systems, 493 losartan potassium, 515 eptastigmine, 285 nitroglycerin, 390 Proteinuria fenoldopam, A932 nizatidine, 1071 ACE therapy in renal disease and, 87 fluocortolone, A926 noncompartmental analysis of pharmacokinetic PSC833 flurbiprofen, A925 data after oral and intravenous administration, pharmacokinetics, A937 fosinopril, 785 A925 Pseudoephedrine ibuprofen, A925 norverapamil, 1076 efficacy with ibuprofen for nasal congestion, immunopharmacodynamic studies of cyclospor- orlistat, 1103 A929 ine in patieAts awaiting renal transplantation, oxprenolol, A939 pharmacokinetics, 259 967 pentamidine, 1166 Psoriasis nefazodone, 1109 phenytoin, A928 cyclosporine A pharmacokinetics in, 865 norverapamil, 1083 pravastatin, 142 propranolol, 1109 propranolol, 374, 885, 1109 Quinine triamcinolone acetonide, 1187 PSC833, A937 for leg cramps, 588 verapamil, 1083 pseudoephedrine, 259 Pharmacoepidemiology retinoids, A930 Radiofrequency Ablation aging effects on antipyrine clearance, 895 scopolamine, A922 inability to tolerate long term drug therapy as in- intra- and interethnic variability in reduced hal- sibutramine, A927, A928 dication for radiofrequency catheter ablation operidol to haloperidol ratios, 128 sotalol, A928 of supraventricular arrhythmias, A927 Pharmacogenetics tamoxifen, A936 Ramipril antipyrine metabolism and acetylation pheno- testosterone, A923 decrease of chlorthalidone-induced loss of mag- type in health and chronic liver diseases, 615 trandolapril, A922 nesium and potassium in hypertension by, Pharmacokinetics triamcinolone acetonide, 302, 1187 1150 amitriptyline, 17 venlafaxine, 404 Renal Disease ardeparin, 1194 verapamil, 163, A922, 1076 ACE therapy in, 87 aspirin, 1181 zidovudine, 856 bepridil pharmacokinetics in, 379 atenolol, 268, 807 Phentolamine dosing of antihypertensive agents in renal in- atorvastatin, 990 antagonism of norepinephrine-induced hand sufficiency, 73 beprid1i37l, ,37 9 vein constriction, 170 immunopharmacodynamic studies of cyclogpor- bespiridine hydrochloride, 688 Phenylacetate ine in patients awaiting renal transplantation, BRL 49653C, A926 disposition, 368 967 1216 individualized approach to hypertension in, 98 Sumatriptan Succinate Transplantation. See Organ Transplantation Renal Function. See also Renal Disease interaction with butorphanol tartrate nasal Trauma ACE therapy in renal disease, 87 spray, 432 ceftizoxime in trauma celiotomy, 1046 antihypertensive agents in diabetic patients, 73 Surrogate Biochemical Markers Triamcinolone Acetonide dosing of antihypertensive agents in renal in- clinical pharmacology and, 441 pharmacokinetics, 302, 1187 sufficiency, 81 development, 464 pharmacodynamics, 1187 individualized approach to hypertensive pa- Trimipramine tients with renal disease, 98 Tacrine enantiomers of, A938 metformin pharmacokinetics and, 1094 interaction with warfarin, 526 Tyramine misoprostol pharmacokinetics, 384 Tacrolimus adverse effects, 633 over-the-counter analgesics and, 454 ciprofloxacin and, A924 renal and limb vasodilation during acute beta- Tamoxifen Vaccines adrenoreceptor blockade with indenolol, 176 with cytotoxic drugs for non-Hodgkin’s lym- tetanus-diphtheria vaccine and tetanus immune symposium from 1993 annual meeting of Ameri- phoma, A936 globulin interaction, 420 can College of Clinical Pharmacology, 72 pharmacokinetics, A936 Valproate verapamil effects on nephrotoxic potential of Telec ication clearance value estimation in children, 1020 gentamicin, 196 training utilizing, A934 Valsartan Respiratory Illness Terazosin pressor response to angiotensin-II in healthy ibuprofen and naproxen antipyretic efficacy in, glycemic control, cholesterol, and microalbu- males and, A930 A929 minuria in patients with diabetes mellitus and Vasodilation Retinoids hypertension and, A934 felodipine, A938 pharmacokinetics, A930 Testosterone Venipuncture Risperidone pharmacokinetics, A923 EMLA cream efficacy for, A924 haloperidol compared with for schizophrenia, Tetanus-Diphtheria Vaccine Venlafaxine A937 interaction with tetanus immune globulin, 420 interaction with diazepam, 410 Rivastatin Tetanus Immune Globulin metabolism of, A936 interaction with warfarin, 306 interaction with tetanus-diphtheria vaccine, 420 pharmacokinetics, 404 Theophylline Venodilation Schizophrenia interaction with famotidine, 529 amrinone and theophylline venodilatory effects alosetron effects on haloperidol pharmacokinet- interaction with sparfloxacin, A936 compared, 1067 ics, 202 venodilatory effect compared with amrinone, Ventilation haloperidol and risperidone compared for, A937 1067 high-grade nucleoside transport inhibition stim- Scopolamine Ticarcillin ulating, 357 pharmacokinetics, A922 ticarcillin/clavulanic acid dose recommenda- Verapamil Serotonin tions for infants and children, 658 interaction with gentamicin, 196 in cardiovascular and noncardiovascular dis- Time low once-daily doses for mild hypertension, 52 ease, 541 norverapamil pharmacokinetics and pharmaco- moexipril versus, for mild to moderate hyperten- Sibutramine dynamics, 1083 sion, 794 pharmacokinetics, A927, A928 verapamil pharmacokinetics and pharmacody- pharmacodynamics, 1083 Sickle Cell Anemia namics, 1083 pharmacokinetics, 163, A922, 1076, 1083 ketorolac and meperidine compared for painful Tooth Extraction Vitamin A episodes, A937 lornoxicam analgesic effect after surgical re- retinoid pharmacokinetics and, A930 Side Effects. See Adverse Effects; specific drugs moval of mandibular third molars, 606 SNX-111 Toxicity Warfarin safety and tolerability study, A933 anthracycline cardiotoxicity, A935 interaction with losartan, 1008 Sotalol cyclic antidepressant toxicity in children and ad- interaction with nefazodone, 730 pharmacokinetics, A928 olescents, 343 interaction with rivastatin, 306 Sparfloxacin mitoxantrone cardiotoxicity in relapsing remit- interaction with tacrine, 526 interaction with theophylline, A936 ting multiple sclerosis, 627 Stereoselectivity piroxicam, A934 Xanomeline Tartrate verapamil and norverapamil enantiomer phar- verapamil effects on nephrotoxic potential of safety and efficacy in Alzheimer’s disease, 800 macokinetics, 1076 gentamicin, 196 Sudden Death Trandolapril Zidovudine sudden unexplained death in epilepsy, 573, A940 pharmacokinetics, A922 pharmacokinetics, 856

See more

The list of books you might like

Upgrade Premium
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.
DMCA & Copyright: Dear all, most of the website is community built, users are uploading hundred of books everyday, which makes really hard for us to identify copyrighted material, please contact us if you want any material removed.
Copyright @ PDFdrive.to, 2022 | We love our users